TW247275B - - Google Patents

Info

Publication number: TW247275B
Authority: TW; Taiwan
Prior art keywords: particles; methods; maintain; useful; particle size
Prior art date: 1991-01-25

Application number

TW081100510A

Other languages

English (en)

Original Assignee

Sterling Winthrop Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-01-25

Filing date

1992-01-24

Publication date

1995-05-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24595721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW247275(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-01-24 Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc

1995-05-11 Application granted granted Critical

1995-05-11 Publication of TW247275B publication Critical patent/TW247275B/zh

Links

239000002245 particle Substances 0.000 abstract 5
241000124008 Mammalia Species 0.000 abstract 1
239000008186 active pharmaceutical agent Substances 0.000 abstract 1
239000006185 dispersion Substances 0.000 abstract 1
229940088679 drug related substance Drugs 0.000 abstract 1
239000003607 modifier Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0476—Particles, beads, capsules, spheres
- A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
- A61K49/0414—Particles, beads, capsules or spheres
- A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
- A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Nanotechnology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Medical Informatics (AREA)
Molecular Biology (AREA)
Crystallography & Structural Chemistry (AREA)
Dispersion Chemistry (AREA)
Medicinal Preparation (AREA)
Manufacturing Of Micro-Capsules (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Helmets And Other Head Coverings (AREA)
Professional, Industrial, Or Sporting Protective Garments (AREA)
Physical Or Chemical Processes And Apparatus (AREA)

TW081100510A 1991-01-25 1992-01-24 TW247275B (zh)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/647,105 US5145684A (en)	1991-01-25	1991-01-25	Surface modified drug nanoparticles

Publications (1)

Publication Number	Publication Date
TW247275B true TW247275B (zh)	1995-05-11

Family

ID=24595721

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW081100510A TW247275B (zh)	1991-01-25	1992-01-24

Country Status (22)

Country	Link
US (1)	US5145684A (zh)
EP (1)	EP0499299B1 (zh)
JP (1)	JP3602546B2 (zh)
KR (1)	KR100200061B1 (zh)
AT (1)	ATE195416T1 (zh)
CA (1)	CA2059432C (zh)
DE (1)	DE69231345T2 (zh)
DK (1)	DK0499299T3 (zh)
ES (1)	ES2149164T3 (zh)
FI (1)	FI108333B (zh)
GR (1)	GR3034759T3 (zh)
HU (1)	HU221586B (zh)
IE (1)	IE920217A1 (zh)
IL (1)	IL100754A (zh)
MX (1)	MX9200291A (zh)
MY (1)	MY108134A (zh)
NO (1)	NO303668B1 (zh)
NZ (1)	NZ241362A (zh)
PT (1)	PT499299E (zh)
RU (1)	RU2066553C1 (zh)
SG (1)	SG55104A1 (zh)
TW (1)	TW247275B (zh)

Families Citing this family (1210)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5994041A (en) *	1985-04-06	1999-11-30	Eastman Kodak Company	Process for buffering concentrated aqueous slurries
US5552154A (en)	1989-11-06	1996-09-03	The Stehlin Foundation For Cancer Research	Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
AU642066B2 (en) *	1991-01-25	1993-10-07	Nanosystems L.L.C.	X-ray contrast compositions useful in medical imaging
US5552160A (en) *	1991-01-25	1996-09-03	Nanosystems L.L.C.	Surface modified NSAID nanoparticles
US5399363A (en) *	1991-01-25	1995-03-21	Eastman Kodak Company	Surface modified anticancer nanoparticles
SE9101090D0 (sv) *	1991-04-11	1991-04-11	Astra Ab	Process for conditioning of water-soluble substances
US5766635A (en) *	1991-06-28	1998-06-16	Rhone-Poulenc Rorer S.A.	Process for preparing nanoparticles
US6515009B1 (en)	1991-09-27	2003-02-04	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en)	1993-01-28	1998-09-22	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5407659A (en) *	1991-10-22	1995-04-18	Mallinckrodt Medical, Inc.	Treated calcium/oxyanion-containing particles for medical diagnostic imaging
US5342609A (en) *	1991-10-22	1994-08-30	Mallinckrodt Medical, Inc.	Microfluidization of calcium/oxyanion-containing particles
US5344640A (en) *	1991-10-22	1994-09-06	Mallinckrodt Medical, Inc.	Preparation of apatite particles for medical diagnostic imaging
US5916540A (en) *	1994-10-24	1999-06-29	Glaxo Group Limited	Aerosol formulations containing P134A and/or P227 and particulate medicament
PT1086688E (pt) *	1991-12-18	2004-06-30	Minnesota Mining & Mfg	Formulacoes de aerossol em suspensao
US7105152B1 (en)	1991-12-18	2006-09-12	3M Innovative Properties Company	Suspension aerosol formulations
US7101534B1 (en)	1991-12-18	2006-09-05	3M Innovative Properties Company	Suspension aerosol formulations
US6080751A (en) *	1992-01-14	2000-06-27	The Stehlin Foundation For Cancer Research	Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
AU677783B2 (en) *	1992-06-10	1997-05-08	Elan Pharma International Limited	Surface modified nsaid nanoparticles
US5552156A (en) *	1992-10-23	1996-09-03	Ohio State University	Liposomal and micellular stabilization of camptothecin drugs
AU660852B2 (en) *	1992-11-25	1995-07-06	Elan Pharma International Limited	Method of grinding pharmaceutical substances
US5298262A (en) *	1992-12-04	1994-03-29	Sterling Winthrop Inc.	Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) *	1992-12-04	1994-09-13	Sterling Winthrop Inc.	Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) *	1992-12-09	1994-04-12	Sterling Winthrop Inc.	Method to reduce particle size growth during lyophilization
US5340564A (en) *	1992-12-10	1994-08-23	Sterling Winthrop Inc.	Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) *	1992-12-11	1994-08-09	Sterling Winthrop Inc.	Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) *	1992-12-15	1995-07-04	Eastman Kodak Company	Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) *	1992-12-16	1994-10-04	Sterling Winthrop Inc.	Use of purified surface modifiers to prevent particle aggregation during sterilization
US5256328A (en) *	1992-12-16	1993-10-26	Eastman Kodak Company	Liquid toilet bowl cleaner and sanitizer containing halogen donating nanoparticles
US5364550A (en) *	1992-12-16	1994-11-15	Eastman Kodak Company	Liquid detergent composition
US5322679A (en) *	1992-12-16	1994-06-21	Sterling Winthrop Inc.	Iodinated aroyloxy esters
US5326552A (en) *	1992-12-17	1994-07-05	Sterling Winthrop Inc.	Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5354564A (en) *	1992-12-18	1994-10-11	Eastman Kodak Company	Personal care compositions
US6491938B2 (en)	1993-05-13	2002-12-10	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US6663881B2 (en)	1993-01-28	2003-12-16	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) *	1993-01-28	1999-11-09	Neorx Corporation	Therapeutic inhibitor of vascular smooth muscle cells
US5916596A (en)	1993-02-22	1999-06-29	Vivorx Pharmaceuticals, Inc.	Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en)	1993-02-22	2003-03-25	American Bioscience, Inc.	Compositions and methods for administration of pharmacologically active compounds
FR2702160B1 (fr) *	1993-03-02	1995-06-02	Biovecteurs As	Vecteurs particulaires synthétiques et procédé de préparation.
US5849263A (en) *	1993-03-30	1998-12-15	Charlotte-Mecklenburg Hospital Authority	Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5840277A (en) *	1993-03-30	1998-11-24	Charlotte Hospital Authority	Treatment of chronic pulmonary inflammation
US5830436A (en) *	1993-03-30	1998-11-03	Duke University	Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
CH686761A5 (de)	1993-05-27	1996-06-28	Sandoz Ag	Galenische Formulierungen.
US5543158A (en) *	1993-07-23	1996-08-06	Massachusetts Institute Of Technology	Biodegradable injectable nanoparticles
US5635206A (en) *	1994-01-20	1997-06-03	Hoffmann-La Roche Inc.	Process for liposomes or proliposomes
EP0678771B1 (en) *	1994-04-18	2001-11-21	Eastman Kodak Company	Stable aqueous solid particle dispersions
US5468598A (en) *	1994-04-18	1995-11-21	Eastman Kodak Company	Solid particle dispersions for imaging systems
US5500331A (en) *	1994-05-25	1996-03-19	Eastman Kodak Company	Comminution with small particle milling media
US5478705A (en) *	1994-05-25	1995-12-26	Eastman Kodak Company	Milling a compound useful in imaging elements using polymeric milling media
US5513803A (en) *	1994-05-25	1996-05-07	Eastman Kodak Company	Continuous media recirculation milling process
TW384224B (en) *	1994-05-25	2000-03-11	Nano Sys Llc	Method of preparing submicron particles of a therapeutic or diagnostic agent
US5587143A (en) *	1994-06-28	1996-12-24	Nanosystems L.L.C.	Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US6007845A (en) *	1994-07-22	1999-12-28	Massachusetts Institute Of Technology	Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5626862A (en)	1994-08-02	1997-05-06	Massachusetts Institute Of Technology	Controlled local delivery of chemotherapeutic agents for treating solid tumors
US20110196039A9 (en) *	1994-10-05	2011-08-11	Kaesemeyer Wayne H	Controlled release arginine formulations
DE4440337A1 (de) *	1994-11-11	1996-05-15	Dds Drug Delivery Services Ges	Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5955108A (en) *	1994-12-16	1999-09-21	Quadrant Healthcare (Uk) Limited	Cross-linked microparticles and their use as therapeutic vehicles
US6524557B1 (en) *	1994-12-22	2003-02-25	Astrazeneca Ab	Aerosol formulations of peptides and proteins
US5609998A (en) *	1994-12-29	1997-03-11	Eastman Kodak Company	Process for dispersing concentrated aqueous slurries
US20020048596A1 (en) *	1994-12-30	2002-04-25	Gregor Cevc	Preparation for the transport of an active substance across barriers
US5628981A (en) *	1994-12-30	1997-05-13	Nano Systems L.L.C.	Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5585108A (en) *	1994-12-30	1996-12-17	Nanosystems L.L.C.	Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) *	1994-12-30	1995-11-14	Eastman Kodak Company	Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5560932A (en) *	1995-01-10	1996-10-01	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents
US5716642A (en) *	1995-01-10	1998-02-10	Nano Systems L.L.C.	Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5665331A (en) *	1995-01-10	1997-09-09	Nanosystems L.L.C.	Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) *	1995-01-10	1997-09-02	Nanosystems L.L.C.	Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) *	1995-01-24	1996-10-29	Nano Systems L.L.C.	Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5520904A (en) *	1995-01-27	1996-05-28	Mallinckrodt Medical, Inc.	Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
US5571536A (en) *	1995-02-06	1996-11-05	Nano Systems L.L.C.	Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
PT808154E (pt) *	1995-02-06	2001-06-29	Elan Pharma Int Ltd	Formulacoes de compostos sob a forma de dispersoes em nanoparticulas em oleos ou acidos gordos digestiveis
US5665330A (en) *	1995-02-08	1997-09-09	Nano Systems Llc	Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
US5503723A (en) *	1995-02-08	1996-04-02	Eastman Kodak Company	Isolation of ultra small particles
US5622938A (en) *	1995-02-09	1997-04-22	Nano Systems L.L.C.	Sugar base surfactant for nanocrystals
US5518738A (en) *	1995-02-09	1996-05-21	Nanosystem L.L.C.	Nanoparticulate nsaid compositions
US5591456A (en) *	1995-02-10	1997-01-07	Nanosystems L.L.C.	Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) *	1995-02-13	1996-11-12	Nano Systems L.L.C.	Redispersible nanoparticulate film matrices with protective overcoats
WO1996025181A1 (en) *	1995-02-14	1996-08-22	Nanosystems L.L.C.	Process of preparing lymphography contrast agents
US5543133A (en) *	1995-02-14	1996-08-06	Nanosystems L.L.C.	Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) *	1995-02-14	1996-04-23	Nanosystems Llc	Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) *	1995-02-15	1996-12-03	Nano Systems L.L.C.	Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
WO1996025918A1 (en) *	1995-02-24	1996-08-29	Nanosystems L.L.C.	Aerosols containing nanoparticle dispersions
US5565188A (en) *	1995-02-24	1996-10-15	Nanosystems L.L.C.	Polyalkylene block copolymers as surface modifiers for nanoparticles
US5747001A (en) *	1995-02-24	1998-05-05	Nanosystems, L.L.C.	Aerosols containing beclomethazone nanoparticle dispersions
US5736156A (en) *	1995-03-22	1998-04-07	The Ohio State University	Liposomal anf micellular stabilization of camptothecin drugs
US5605696A (en) *	1995-03-30	1997-02-25	Advanced Cardiovascular Systems, Inc.	Drug loaded polymeric material and method of manufacture
US6428771B1 (en) *	1995-05-15	2002-08-06	Pharmaceutical Discovery Corporation	Method for drug delivery to the pulmonary system
IL118088A0 (en) *	1995-06-07	1996-08-04	Anzon Inc	Colloidal particles of solid flame retardant and smoke suppressant compounds and methods for making them
EP0752245B1 (en) *	1995-07-05	2002-05-22	European Community	Biocompatible and biodegradable nanoparticles designed for proteinaceous drugs absorption and delivery
FR2736550B1 (fr)	1995-07-14	1998-07-24	Sandoz Sa	Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US6458366B1 (en)	1995-09-01	2002-10-01	Corixa Corporation	Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) *	1995-09-01	2003-07-15	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6290969B1 (en) *	1995-09-01	2001-09-18	Corixa Corporation	Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6391338B1 (en) *	1995-09-07	2002-05-21	Biovail Technologies Ltd.	System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5834025A (en)	1995-09-29	1998-11-10	Nanosystems L.L.C.	Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
KR100508910B1 (ko) *	1995-10-17	2006-04-20	알티피 파마 코포레이션	불용성약물방출
US5679138A (en) *	1995-11-30	1997-10-21	Eastman Kodak Company	Ink jet inks containing nanoparticles of organic pigments
US5662279A (en) *	1995-12-05	1997-09-02	Eastman Kodak Company	Process for milling and media separation
US20050267302A1 (en) *	1995-12-11	2005-12-01	G.D. Searle & Co.	Eplerenone crystalline form exhibiting enhanced dissolution rate
US5968543A (en) *	1996-01-05	1999-10-19	Advanced Polymer Systems, Inc.	Polymers with controlled physical state and bioerodibility
US5686133A (en) *	1996-01-31	1997-11-11	Port Systems, L.L.C.	Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5611344A (en) *	1996-03-05	1997-03-18	Acusphere, Inc.	Microencapsulated fluorinated gases for use as imaging agents
NZ331460A (en) *	1996-03-05	1998-12-23	Acusphere Inc	Microencapsulated fluorinated gases for use as imaging agents
EP0914096B1 (en) *	1996-05-17	2003-08-13	Elan Drug Delivery Limited	Microparticles and their use in wound therapy
CN1219872A (zh)	1996-05-24	1999-06-16	血管技术药物公司	治疗或预防身体通道疾病的组合物和方法
USRE37053E1 (en)	1996-05-24	2001-02-13	Massachusetts Institute Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US6254854B1 (en)	1996-05-24	2001-07-03	The Penn Research Foundation	Porous particles for deep lung delivery
US20020052310A1 (en) *	1997-09-15	2002-05-02	Massachusetts Institute Of Technology The Penn State Research Foundation	Particles for inhalation having sustained release properties
US6652837B1 (en) *	1996-05-24	2003-11-25	Massachusetts Institute Of Technology	Preparation of novel particles for inhalation
US5874064A (en)	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US6503480B1 (en) *	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5726154A (en) *	1996-06-28	1998-03-10	University Of Utah Research Foundation	Stabilization and oral delivery of calcitonin
US5837221A (en) *	1996-07-29	1998-11-17	Acusphere, Inc.	Polymer-lipid microencapsulated gases for use as imaging agents
US5935890A (en)	1996-08-01	1999-08-10	Glcc Technologies, Inc.	Stable dispersions of metal passivation agents and methods for making them
US7255877B2 (en) *	1996-08-22	2007-08-14	Jagotec Ag	Fenofibrate microparticles
US6465016B2 (en)	1996-08-22	2002-10-15	Research Triangle Pharmaceuticals	Cyclosporiine particles
US7060253B1 (en) *	1996-09-20	2006-06-13	Mundschenk David D	Topical formulations and delivery systems
GB9622173D0 (en) *	1996-10-24	1996-12-18	Glaxo Group Ltd	Particulate Products
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
FR2758459B1 (fr) *	1997-01-17	1999-05-07	Pharma Pass	Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US6416778B1 (en) *	1997-01-24	2002-07-09	Femmepharma	Pharmaceutical preparations and methods for their regional administration
US5993856A (en) *	1997-01-24	1999-11-30	Femmepharma	Pharmaceutical preparations and methods for their administration
US6045829A (en) *	1997-02-13	2000-04-04	Elan Pharma International Limited	Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) *	1997-02-13	1998-08-20	Nanosystems Llc	Formulations of nanoparticle naproxen tablets
CO4920215A1 (es) *	1997-02-14	2000-05-29	Novartis Ag	Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20050004049A1 (en) *	1997-03-11	2005-01-06	Elan Pharma International Limited	Novel griseofulvin compositions
US5989591A (en) *	1997-03-14	1999-11-23	American Home Products Corporation	Rapamycin formulations for oral administration
CA2230748C (en) *	1997-03-14	2010-08-03	American Home Products Corporation	Rapamycin formulations for oral administration
US6193954B1 (en) *	1997-03-21	2001-02-27	Abbott Laboratories	Formulations for pulmonary delivery of dopamine agonists
AU7133898A (en) *	1997-04-18	1998-11-13	Vertex Pharmaceuticals Incorporated	Nanosized aspartyl protease inhibitors
AU732455C (en)	1997-05-08	2002-09-05	Merck Sharp & Dohme Limited	Substituted 1,2,4-triazolo{3,4-a}phthalazine derivatives as gaba alpha 5 ligands
IT1292142B1 (it) *	1997-06-12	1999-01-25	Maria Rosa Gasco	Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
WO1998057648A1 (en) *	1997-06-16	1998-12-23	Vertex Pharmaceuticals Incorporated	Methods of increasing the bioavailability of stable crystal polymorphs of a compound
SG165156A1 (en)	1997-06-27	2010-10-28	Abraxis Bioscience Llc	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
NZ502500A (en) *	1997-06-27	2002-03-28	Vivorx Pharmaceuticals Inc	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
UA62983C2 (en) *	1997-09-12	2004-01-15		Pharmaceutical composition for treating or preventing dysmenorrhea or premature labor
US7052678B2 (en)	1997-09-15	2006-05-30	Massachusetts Institute Of Technology	Particles for inhalation having sustained release properties
US20060165606A1 (en)	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en)	1997-09-29	2001-10-30	Inhale Therapeutic Systems, Inc.	Stabilized preparations for use in metered dose inhalers
US6946117B1 (en) *	1997-09-29	2005-09-20	Nektar Therapeutics	Stabilized preparations for use in nebulizers
US6565885B1 (en)	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20020017295A1 (en) *	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6919070B1 (en) *	1997-10-17	2005-07-19	Zakrytoe Aktsionernoe Obschestvo “OSTIM”	Stomatic composition
UA72189C2 (uk) *	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
GB9726543D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Novel compositions
US6086376A (en) *	1998-01-30	2000-07-11	Rtp Pharma Inc.	Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
CZ291302B6 (cs)	1998-02-25	2003-01-15	Merck Sharp & Dohme Limited	Substituovaný 1,2,4-triazolo[3,4-a]ftalazinový derivát
US6287693B1 (en) *	1998-02-25	2001-09-11	John Claude Savoir	Stable shaped particles of crystalline organic compounds
ZA991922B (en) *	1998-03-11	1999-09-13	Smithkline Beecham Corp	Novel compositions of eprosartan.
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
US6337092B1 (en)	1998-03-30	2002-01-08	Rtp Pharma Inc.	Composition and method of preparing microparticles of water-insoluble substances
CA2326456C (en)	1998-03-30	2008-12-23	Rtp Pharma Inc.	Composition and method of preparing microparticles of water-insoluble substances
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
WO1999061001A1 (en)	1998-05-29	1999-12-02	Rtp Pharma Inc.	Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
US6153225A (en) *	1998-08-13	2000-11-28	Elan Pharma International Limited	Injectable formulations of nanoparticulate naproxen
US7097849B2 (en)	1998-08-19	2006-08-29	Jagotec Ag	Injectable aqueous dispersions of propofol
US6956021B1 (en)	1998-08-25	2005-10-18	Advanced Inhalation Research, Inc.	Stable spray-dried protein formulations
US6165506A (en) *	1998-09-04	2000-12-26	Elan Pharma International Ltd.	Solid dose form of nanoparticulate naproxen
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
EP1117384A1 (en) *	1998-10-01	2001-07-25	Elan Pharma International Limited	Controlled release nanoparticulate compositions
US20040013613A1 (en) *	2001-05-18	2004-01-22	Jain Rajeev A	Rapidly disintegrating solid oral dosage form
US8236352B2 (en) *	1998-10-01	2012-08-07	Alkermes Pharma Ireland Limited	Glipizide compositions
US20080213378A1 (en) *	1998-10-01	2008-09-04	Elan Pharma International, Ltd.	Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
NZ511442A (en) *	1998-11-02	2003-02-28	Elan Corp Plc	Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US20070160675A1 (en) *	1998-11-02	2007-07-12	Elan Corporation, Plc	Nanoparticulate and controlled release compositions comprising a cephalosporin
US20090297602A1 (en) *	1998-11-02	2009-12-03	Devane John G	Modified Release Loxoprofen Compositions
US6375986B1 (en)	2000-09-21	2002-04-23	Elan Pharma International Ltd.	Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US7521068B2 (en)	1998-11-12	2009-04-21	Elan Pharma International Ltd.	Dry powder aerosols of nanoparticulate drugs
US6428814B1 (en) *	1999-10-08	2002-08-06	Elan Pharma International Ltd.	Bioadhesive nanoparticulate compositions having cationic surface stabilizers
GB9824897D0 (en)	1998-11-12	1999-01-06	Merck Sharp & Dohme	Therapeutic compounds
OA11677A (en) *	1998-11-12	2005-01-12	Smithkline Beecham Plc	Pharmaceutical composition for modified release ofan insulin sensitiser and another antidiabetic agent.
US6969529B2 (en) *	2000-09-21	2005-11-29	Elan Pharma International Ltd.	Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
WO2000030616A1 (en)	1998-11-20	2000-06-02	Rtp Pharma Inc.	Dispersible phospholipid stabilized microparticles
NZ568033A (en) *	1998-11-27	2011-04-29	Darwin Discovery Ltd	Compositions and methods for increasing bone mineralization
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
DE19856432A1 (de) *	1998-12-08	2000-06-15	Basf Ag	Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
SI1031346T1 (en)	1999-01-27	2002-08-31	Idea Ag	Noninvasive vaccination through the skin
PT1031347E (pt)	1999-01-27	2002-09-30	Idea Ag	Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
US6294192B1 (en)	1999-02-26	2001-09-25	Lipocine, Inc.	Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) *	1999-06-30	2001-07-31	Lipocine Inc.	Clear oil-containing pharmaceutical compositions
US7374779B2 (en) *	1999-02-26	2008-05-20	Lipocine, Inc.	Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6761903B2 (en)	1999-06-30	2004-07-13	Lipocine, Inc.	Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6270806B1 (en)	1999-03-03	2001-08-07	Elan Pharma International Limited	Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) *	1999-03-08	2001-07-31	Klan Pharma International Ltd.	Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
EG23951A (en)	1999-03-25	2008-01-29	Otsuka Pharma Co Ltd	Cilostazol preparation
US6383471B1 (en)	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US8143386B2 (en) *	1999-04-07	2012-03-27	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis antigens and their uses
AU4225700A (en) *	1999-04-12	2000-11-14	Dow Agrosciences Llc	Aqueous dispersions of agricultural chemicals
US6491239B2 (en)	1999-05-06	2002-12-10	Eastman Kodak Company	Process for milling compounds
US6309749B1 (en)	1999-05-06	2001-10-30	Eastman Kodak Company	Ceramic milling media containing tetragonal zirconia
US6444223B1 (en)	1999-05-28	2002-09-03	Alkermes Controlled Therapeutics, Inc.	Method of producing submicron particles of a labile agent and use thereof
EP1185371B2 (en)	1999-06-01	2008-11-12	Elan Pharma International Limited	Small-scale mill and method thereof
US20090104273A1 (en) *	1999-06-22	2009-04-23	Elan Pharma International Ltd.	Novel nifedipine compositions
US20040115134A1 (en) *	1999-06-22	2004-06-17	Elan Pharma International Ltd.	Novel nifedipine compositions
US6555139B2 (en)	1999-06-28	2003-04-29	Wockhardt Europe Limited	Preparation of micron-size pharmaceutical particles by microfluidization
PT1808438E (pt)	1999-06-29	2015-01-14	Mannkind Corp	Purificação e estabilização de péptidos e proteínas em agentes farmacêuticos
US9006175B2 (en) *	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
US6309663B1 (en)	1999-08-17	2001-10-30	Lipocine Inc.	Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en)	1999-08-17	2002-10-01	Lipocine, Inc.	Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6982281B1 (en) *	2000-11-17	2006-01-03	Lipocine Inc	Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
AU5409699A (en) *	1999-07-05	2001-01-22	Idea Ag	A method for the improvement of transport across adaptable semi-permeable barriers
US6576224B1 (en) *	1999-07-06	2003-06-10	Sinuspharma, Inc.	Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US7863331B2 (en) *	1999-07-09	2011-01-04	Ethypharm	Pharmaceutical composition containing fenofibrate and method for the preparation thereof
FR2795961B1 (fr) *	1999-07-09	2004-05-28	Ethypharm Lab Prod Ethiques	Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US6927210B1 (en)	1999-08-12	2005-08-09	Eli Lilly And Company	Ectoparasiticidal aqueous suspension formulations of spinosyns
WO2001011963A1 (en)	1999-08-12	2001-02-22	Eli Lilly And Company	Oral treatment of companion animals with ectoparasiticidal spinosyns
US6933318B1 (en)	1999-08-12	2005-08-23	Eli Lilly And Company	Topical organic ectoparasiticidal formulations
US20010036481A1 (en) *	1999-08-25	2001-11-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US6749835B1 (en)	1999-08-25	2004-06-15	Advanced Inhalation Research, Inc.	Formulation for spray-drying large porous particles
US7678364B2 (en)	1999-08-25	2010-03-16	Alkermes, Inc.	Particles for inhalation having sustained release properties
WO2001013891A2 (en) *	1999-08-25	2001-03-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
US6656504B1 (en)	1999-09-09	2003-12-02	Elan Pharma International Ltd.	Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
WO2001024820A1 (en) *	1999-10-07	2001-04-12	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
KR20020059653A (ko)	1999-10-29	2002-07-13	그린 마틴, 브라이언 쥐 테슬리	서방성 하이드로코돈 제형
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
US20030203884A1 (en) *	1999-11-09	2003-10-30	Pharmacia Corporation	Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030096798A1 (en) *	1999-11-09	2003-05-22	Williams Gordon H.	Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
AUPQ441699A0 (en)	1999-12-02	2000-01-06	Eli Lilly And Company	Pour-on formulations
CA2362845A1 (en) *	1999-12-08	2001-06-14	Pharmacia Corporation	Eplerenone crystalline form
US20030083493A1 (en) *	1999-12-08	2003-05-01	Barton Kathleen P.	Eplerenone drug substance having high phase purity
WO2001041760A2 (en) *	1999-12-08	2001-06-14	Pharmacia Corporation	Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
UA74539C2 (en)	1999-12-08	2006-01-16	Pharmacia Corp	Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US6251136B1 (en)	1999-12-08	2001-06-26	Advanced Cardiovascular Systems, Inc.	Method of layering a three-coated stent using pharmacological and polymeric agents
US6702849B1 (en)	1999-12-13	2004-03-09	Advanced Cardiovascular Systems, Inc.	Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
WO2001045674A1 (en)	1999-12-20	2001-06-28	Cocensys, Inc.	Process for producing nanometer particles by fluid bed spray-drying
US8771740B2 (en) *	1999-12-20	2014-07-08	Nicholas J. Kerkhof	Process for producing nanoparticles by spray drying
EA006402B1 (ru)	1999-12-23	2005-12-29	Пфайзер Продактс Инк.	Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
GB9930562D0 (en) *	1999-12-23	2000-02-16	Boc Group Plc	Partial oxidation of hydrogen sulphide
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
JP2004501068A (ja) *	2000-01-31	2004-01-15	コラボレイティヴ・テクノロジーズ・インコーポレーテッド	界面活性剤を含まない局所用組成物、及びその迅速な調製方法
WO2001062778A2 (en)	2000-02-23	2001-08-30	Smithkline Beecham Biologicals S.A.	Tumour-specific animal proteins
WO2001062893A2 (en) *	2000-02-25	2001-08-30	Corixa Corporation	Compounds and methods for diagnosis and immunotherapy of tuberculosis
CA2400172C (en) *	2000-02-28	2010-04-20	Genesegues, Inc.	Nanocapsule encapsulation system and method
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AUPQ634300A0 (en) *	2000-03-20	2000-04-15	Eli Lilly And Company	Synergistic formulations
US7153525B1 (en) *	2000-03-22	2006-12-26	The University Of Kentucky Research Foundation	Microemulsions as precursors to solid nanoparticles
WO2001070672A2 (en)	2000-03-23	2001-09-27	Elan Pharmaceuticals, Inc.	Compounds and methods to treat alzheimer's disease
US6992081B2 (en)	2000-03-23	2006-01-31	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
GB0009773D0 (en) *	2000-04-19	2000-06-07	Univ Cardiff	Particulate composition
CA2407027C (en)	2000-04-20	2011-02-15	Rtp Pharma Inc.	Improved water-insoluble drug particle process
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
ATE389455T1 (de)	2000-05-10	2008-04-15	Jagotec Ag	Zerkleinerung mittels mahlkörper
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en)	2000-05-10	2018-06-25	Novartis Ag	Phospholipid based powders for drug delivery
US6316029B1 (en) *	2000-05-18	2001-11-13	Flak Pharma International, Ltd.	Rapidly disintegrating solid oral dosage form
US20040156872A1 (en) *	2000-05-18	2004-08-12	Elan Pharma International Ltd.	Novel nimesulide compositions
AR035642A1 (es) *	2000-05-26	2004-06-23	Pharmacia Corp	Uso de una composicion de celecoxib para el alivio rapido del dolor
EP1542732B1 (en)	2000-06-20	2009-09-16	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
US6849713B2 (en) *	2000-06-27	2005-02-01	Genelabs Technologies, Inc.	Compounds possessing antibacterial, antifungal or antitumor activity
AU2001273149A1 (en)	2000-06-28	2002-01-08	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
AU2001271686A1 (en) *	2000-06-30	2002-01-14	Elan Pharmaceuticals, Inc.	Compounds to treat alzheimer's disease
PE20020276A1 (es)	2000-06-30	2002-04-06	Elan Pharm Inc	COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
US20030096864A1 (en) *	2000-06-30	2003-05-22	Fang Lawrence Y.	Compounds to treat alzheimer's disease
US6846813B2 (en) *	2000-06-30	2005-01-25	Pharmacia & Upjohn Company	Compounds to treat alzheimer's disease
EP1666452A2 (en)	2000-06-30	2006-06-07	Elan Pharmaceuticals, Inc.	Compounds to treat Alzheimer's disease
IN192160B (zh) *	2000-07-17	2004-02-28	Ranbaxy Lab
US6656505B2 (en)	2000-07-21	2003-12-02	Alpharma Uspd Inc.	Method for forming an aqueous flocculated suspension
US6716829B2 (en)	2000-07-27	2004-04-06	Pharmacia Corporation	Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
US20040235809A1 (en) *	2000-07-27	2004-11-25	Alexander John C	Epoxy steroidal aldosterone antagonist and beta-adremergic antagonist combination therepy for treatment of congestive heart failure
AU2001285318A1 (en) *	2000-08-28	2002-03-13	Pharmacia Corporation	Use of an aldosterone receptor antagonist to improve cognitive function
US6634576B2 (en)	2000-08-31	2003-10-21	Rtp Pharma Inc.	Milled particles
US8586094B2 (en)	2000-09-20	2013-11-19	Jagotec Ag	Coated tablets
US7998507B2 (en) *	2000-09-21	2011-08-16	Elan Pharma International Ltd.	Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20030181411A1 (en) *	2002-03-20	2003-09-25	Elan Pharma International Ltd.	Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20080241070A1 (en) *	2000-09-21	2008-10-02	Elan Pharma International Ltd.	Fenofibrate dosage forms
US7198795B2 (en) *	2000-09-21	2007-04-03	Elan Pharma International Ltd.	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20030224058A1 (en) *	2002-05-24	2003-12-04	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US7276249B2 (en) *	2002-05-24	2007-10-02	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
EP1337244A4 (en)	2000-10-30	2006-01-11	Euro Celtique Sa	HYDROCODON FORMULATIONS WITH CONTROLLED RELEASE
US6756062B2 (en)	2000-11-03	2004-06-29	Board Of Regents University Of Texas System	Preparation of drug particles using evaporation precipitation into aqueous solutions
US8551526B2 (en) *	2000-11-03	2013-10-08	Board Of Regents, The University Of Texas System	Preparation of drug particles using evaporation precipitation into aqueous solutions
US20030198679A1 (en) *	2000-11-08	2003-10-23	Kundu Subhas C.	Flocculated pharmaceutical suspensions and methods for actives
SK7092003A3 (en) *	2000-11-09	2004-06-08	Neopharm Inc	SN-38 lipid complexes and methods of use
GB0028583D0 (en) *	2000-11-23	2001-01-10	Merck Sharp & Dohme	Therapeutic compounds
PT1337239E (pt)	2000-11-30	2010-01-26	Vectura Ltd	Partículas servindo à preparação de uma composição farmacêutica
PT2283818T (pt)	2000-11-30	2017-10-09	Vectura Ltd	Método de preparação de partículas para utilização numa composição farmacêutica
EP1339390A2 (en) *	2000-12-06	2003-09-03	Pharmacia Corporation	Laboratory scale milling process
HUP0400683A2 (hu) *	2000-12-11	2004-06-28	Takeda Chemical Industries, Ltd.	HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
DE10063092A1 (de) *	2000-12-18	2002-06-20	Henkel Kgaa	Nanoskalige Materialien in Hygiene-Produkten
DE10063090A1 (de) *	2000-12-18	2002-06-20	Henkel Kgaa	Nanoskaliges ZnO in Hygiene-Produkten
US6982251B2 (en) *	2000-12-20	2006-01-03	Schering Corporation	Substituted 2-azetidinones useful as hypocholesterolemic agents
US20050048126A1 (en)	2000-12-22	2005-03-03	Barrett Rabinow	Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
DK1347747T3 (da) *	2000-12-22	2006-04-10	Baxter Int	Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler
US20030096013A1 (en) *	2000-12-22	2003-05-22	Jane Werling	Preparation of submicron sized particles with polymorph control
RU2272616C2 (ru) *	2000-12-22	2006-03-27	Бакстер Интернэшнл Инк.	Способ получения суспензий субмикронных частиц
US6884436B2 (en) *	2000-12-22	2005-04-26	Baxter International Inc.	Method for preparing submicron particle suspensions
US20040022862A1 (en) *	2000-12-22	2004-02-05	Kipp James E.	Method for preparing small particles
US9700866B2 (en)	2000-12-22	2017-07-11	Baxter International Inc.	Surfactant systems for delivery of organic compounds
US6977085B2 (en) *	2000-12-22	2005-12-20	Baxter International Inc.	Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) *	2000-12-22	2007-03-20	Baxter International Inc.	Polymorphic form of itraconazole
US6951656B2 (en) *	2000-12-22	2005-10-04	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
US20030072807A1 (en) *	2000-12-22	2003-04-17	Wong Joseph Chung-Tak	Solid particulate antifungal compositions for pharmaceutical use
US6623761B2 (en)	2000-12-22	2003-09-23	Hassan Emadeldin M.	Method of making nanoparticles of substantially water insoluble materials
US8067032B2 (en) *	2000-12-22	2011-11-29	Baxter International Inc.	Method for preparing submicron particles of antineoplastic agents
US7037528B2 (en) *	2000-12-22	2006-05-02	Baxter International Inc.	Microprecipitation method for preparing submicron suspensions
WO2002062755A2 (en) *	2000-12-27	2002-08-15	Genelabs Technologies, Inc.	Polyamide analogs as dna minor groove binders
US20020141946A1 (en) *	2000-12-29	2002-10-03	Advanced Inhalation Research, Inc.	Particles for inhalation having rapid release properties
WO2002053190A2 (en) *	2000-12-29	2002-07-11	Advanced Inhalation Research, Inc.	Particles for inhalation having sustained release properties
US20030125236A1 (en) *	2000-12-29	2003-07-03	Advenced Inhalation Research, Inc.	Particles for inhalation having rapid release properties
FI20010115A0 (fi) *	2001-01-18	2001-01-18	Orion Corp	Menetelmä nanopartikkelien valmistamiseksi
DE60220269T2 (de) *	2001-01-26	2008-01-17	Schering Corp.	Kombinationen eines hemmers der sterolabsorption und eines kardiovaskulären wirkstoffes zur behandlung von kardiovaskulären indikationen
CA2434033A1 (en) *	2001-01-26	2002-08-01	Schering Corporation	Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PT1355644E (pt) *	2001-01-26	2006-11-30	Schering Corp	Utilização de compostos azetidinona substituídos para o tratamento de sitosterolemia
US7071181B2 (en) *	2001-01-26	2006-07-04	Schering Corporation	Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
ES2274013T3 (es) *	2001-01-26	2007-05-16	Schering Corporation	Combinaciones de activador(es) del receptor activado por el proliferador de los peroxisomas (ppar) e inhibidor(es)m de la absorcion de estelores y tratamientos para trastornos vasculares.
AR032403A1 (es) *	2001-01-26	2003-11-05	Schering Corp	Combinaciones de inhibidor(es) de la absorcion de esterol con modificador(es) sanguineos para tratar cuadros vasculares
JP2004517916A (ja) *	2001-01-26	2004-06-17	シェーリング　コーポレイション	ニコチン酸およびその誘導体ならびにステロール吸収阻害剤の併用、および血管適応症の治療
AU2002243760A1 (en) *	2001-01-30	2002-08-12	Board Of Regents University Of Texas System	Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040022861A1 (en) *	2001-01-30	2004-02-05	Williams Robert O.	Process for production of nanoparticles and microparticles by spray freezing into liquid
US6509027B2 (en)	2001-02-12	2003-01-21	Supergen, Inc.	Injectable pharmaceutical composition comprising coated particles of camptothecin
US20020150615A1 (en) *	2001-02-12	2002-10-17	Howard Sands	Injectable pharmaceutical composition comprising microdroplets of a camptothecin
US6497896B2 (en)	2001-02-12	2002-12-24	Supergen, Inc.	Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
JP3386052B2 (ja) *	2001-02-13	2003-03-10	トヨタ自動車株式会社	ポンプ装置
ATE343567T1 (de)	2001-02-14	2006-11-15	Tibotec Pharm Ltd	Breitspektrum 2-(substituierte-amino)- benzothiazol-sulfonamide hiv protease inhibitoren
CN1273112C (zh) *	2001-02-22	2006-09-06	斯凯伊药品加拿大公司	具有减少进食－禁食作用的贝特－它汀组合
DE10114244A1 (de) *	2001-03-22	2002-10-02	Heraeus Kulzer Gmbh & Co Kg	Antibiotikum-/Antibiotika-Zubereitung mit retardierender Wirkstofffreisetzung
AU2002257104B2 (en) *	2001-04-03	2006-02-09	Merck Sharp & Dohme Corp.	Antifungal composition with enhanced bioavailability
CA2441108A1 (en) *	2001-04-05	2002-10-17	Universite Laval	Process for making delivery matrix and uses thereof
AR035819A1 (es)	2001-04-09	2004-07-14	Tibotec Pharm Ltd	2-(amino sustituido)-benzoxazol sulfonamidas, inhibidoras de la proteasa del hiv, composiciones farmaceuticas que comprenden dichos compuestos, metodo in vitro para inhibir la replicacion retroviral y uso de dichos compuestos en la fabricacion de medicamentos
US20040126900A1 (en) *	2001-04-13	2004-07-01	Barry Stephen E	High affinity peptide- containing nanoparticles
US6667344B2 (en)	2001-04-17	2003-12-23	Dey, L.P.	Bronchodilating compositions and methods
US20030157161A1 (en) *	2001-05-01	2003-08-21	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
JP2004529934A (ja) *	2001-05-01	2004-09-30	アンジオテックファーマシューティカルズ，インコーポレイテッド	抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用
US6613083B2 (en)	2001-05-02	2003-09-02	Eckhard Alt	Stent device and method
ITMO20010086A1 (it) *	2001-05-08	2002-11-08	Worgas Bruciatori Srl	Metodo ed apparato per ridurre le emissioni di biossido di azoto (no2)in un apparecchio da riscaldamento senza canna fumaria
CA2446788A1 (en)	2001-05-09	2002-11-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
US7622490B2 (en)	2001-05-11	2009-11-24	Tibotec Pharmaceuticals, Ltd.	Broadspecturm 2-amino-benzoxazole sulfonamide HIV protease inhibitors
DE10125290B4 (de) *	2001-05-15	2005-04-14	Siemens Ag	Verfahren zum Aufbereiten von Nano-Dispersanten
EP1392440A2 (en) *	2001-05-23	2004-03-03	E.I. Du Pont De Nemours And Company	High pressure media mill
AU2002308778A1 (en) *	2001-05-25	2002-12-09	Schering Corporation	Use of azetidinone substituted derivatives in the treatment of alzheimer's disease
WO2003030864A1 (en) *	2001-05-29	2003-04-17	Neopharm, Inc.	Liposomal formulation of irinotecan
US6976647B2 (en) *	2001-06-05	2005-12-20	Elan Pharma International, Limited	System and method for milling materials
EP1392441B1 (en) *	2001-06-05	2008-07-23	Elan Pharma International Limited	System and method for milling materials
US6730319B2 (en)	2001-06-06	2004-05-04	Hoffmann-La Roche Inc.	Pharmaceutical compositions having depressed melting points
US20040173147A1 (en) *	2001-06-07	2004-09-09	Figueroa Iddys D.	Application of a bioactive agent to a delivery substrate
US20040173146A1 (en) *	2001-06-07	2004-09-09	Figueroa Iddys D.	Application of a bioactive agent to a delivery substrate
US6962715B2 (en) *	2001-10-24	2005-11-08	Hewlett-Packard Development Company, L.P.	Method and dosage form for dispensing a bioactive substance
EP1395251A2 (en)	2001-06-13	2004-03-10	Elan Pharmaceuticals, Inc.	Aminediols as agents for the treatment of alzheimer's disease
GB0114532D0 (en) *	2001-06-14	2001-08-08	Jagotec Ag	Novel compositions
EP1269994A3 (en) *	2001-06-22	2003-02-12	Pfizer Products Inc.	Pharmaceutical compositions comprising drug and concentration-enhancing polymers
DE60203506T2 (de) *	2001-06-22	2006-02-16	Marie Lindner	Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
JP2004534811A (ja) *	2001-06-22	2004-11-18	ファイザー・プロダクツ・インク	ポリマーと薬剤の集合体を含む医薬組成物
US7758890B2 (en)	2001-06-23	2010-07-20	Lyotropic Therapeutics, Inc.	Treatment using dantrolene
CA2452039A1 (en) *	2001-06-27	2003-01-09	Elan Pharmaceuticals, Inc.	Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
BR0211118A (pt) *	2001-07-10	2004-10-26	Elan Pharm Inc	Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
MXPA04000337A (es) *	2001-07-10	2004-07-23	Upjohn Co	Amindioles para tratamiento de enfermedad de alzheimer.
GB0208742D0 (en)	2002-04-17	2002-05-29	Bradford Particle Design Ltd	Particulate materials
US20030220310A1 (en) *	2001-07-27	2003-11-27	Schuh Joseph R.	Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20080305173A1 (en) *	2001-07-31	2008-12-11	Beuford Arlie Bogue	Amorphous drug beads
ATE365537T1 (de) *	2001-08-06	2007-07-15	Astrazeneca Ab	Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct)
GB0119480D0 (en) *	2001-08-09	2001-10-03	Jagotec Ag	Novel compositions
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US20030049323A1 (en) *	2001-08-29	2003-03-13	Hitt James E.	Process to precipitate drug particles
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
DK1435786T3 (da) *	2001-09-17	2011-10-03	Lilly Co Eli	Pesticide formuleringer
WO2003024425A1 (en) *	2001-09-19	2003-03-27	Elan Pharma International, Ltd.	Nanoparticulate insulin formulations
CN101785772A (zh) *	2001-09-21	2010-07-28	先灵公司	使用甾醇吸收抑制剂治疗或预防脉管炎的方法
US20030119808A1 (en) *	2001-09-21	2003-06-26	Schering Corporation	Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
US7056906B2 (en) *	2001-09-21	2006-06-06	Schering Corporation	Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) *	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
JP2005504091A (ja) *	2001-09-21	2005-02-10	シェーリング　コーポレイション	ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
BR0212822A (pt) *	2001-09-25	2005-08-30	Pharmacia Corp	Formas cristalinas de n-(2-hidroxiacetil)-5-(4-piperdil)-4-(4-pirimidinil)-3-(4-clo rofenil)pirazol e composições farmacêuticas contendo as mesmas
US20060003012A9 (en) *	2001-09-26	2006-01-05	Sean Brynjelsen	Preparation of submicron solid particle suspensions by sonication of multiphase systems
EP1429749A2 (en)	2001-09-26	2004-06-23	Baxter International Inc.	Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7544681B2 (en) *	2001-09-27	2009-06-09	Ramot At Tel Aviv University Ltd.	Conjugated psychotropic drugs and uses thereof
US20050191359A1 (en) *	2001-09-28	2005-09-01	Solubest Ltd.	Water soluble nanoparticles and method for their production
US20050233003A1 (en) *	2001-09-28	2005-10-20	Solubest Ltd.	Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
US20050227911A1 (en) *	2001-09-28	2005-10-13	Solubest Ltd.	Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) *	2001-09-28	2005-04-12	Solubest Ltd.	Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
AU2002343483A1 (en)	2001-10-04	2003-04-14	Elan Pharmaceuticals, Inc.	Hydroxypropylamines
CA2463495C (en) *	2001-10-12	2011-05-24	Baudax Bio, Inc.	Compositions having a combination of immediate release and controlled release characteristics
CA2461556A1 (en) *	2001-10-15	2003-04-24	Crititech, Inc.	Compositions and methods for delivery of microparticles of poorly water soluble drugs and methods of treatment
US7112340B2 (en) *	2001-10-19	2006-09-26	Baxter International Inc.	Compositions of and method for preparing stable particles in a frozen aqueous matrix
TWI330183B (zh) *	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
EP1450863A4 (en) *	2001-11-07	2009-01-07	Imcor Pharmaceutical Company	PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS
IL161881A0 (en) *	2001-11-08	2005-11-20	Upjohn Co	N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
US7700851B2 (en) *	2001-11-13	2010-04-20	U.S. Smokeless Tobacco Company	Tobacco nicotine demethylase genomic clone and uses thereof
CA2467476A1 (en) *	2001-11-19	2003-05-30	Pharmacia & Upjohn Company	Amino diols useful in the treatment of alzheimer's disease
GB0127805D0 (en) *	2001-11-20	2002-01-09	Smithkline Beecham Plc	Pharmaceutical composition
PT1455755E (pt) *	2001-11-20	2013-06-18	Civitas Therapeutics Inc	Composições particuladas melhoradas para distribuição pulmonar
WO2003043603A1 (en) *	2001-11-20	2003-05-30	Advanced Inhalation Research, Inc.	Particulate compositions for improving solubility of poorly soluble agents
UA76810C2 (uk) †	2001-12-10	2006-09-15	Мерк Енд Ко., Інк.	Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
DK1581119T3 (da)	2001-12-17	2013-05-13	Corixa Corp	Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
WO2003053411A1 (en)	2001-12-19	2003-07-03	Nektar Therapeutics	Pulmonary delivery of aminoglycosides
MXPA04006017A (es) *	2001-12-20	2005-06-08	Femmepharma Inc	Suministro de farmacos por via vaginal.
MY138657A (en)	2001-12-21	2009-07-31	Tibotec Pharm Ltd	broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
US20030235619A1 (en) *	2001-12-21	2003-12-25	Christine Allen	Polymer-lipid delivery vehicles
IL162183A0 (en) *	2001-12-21	2005-11-20	Celator Technologies Inc	Polymer-lipid delivery vehicles and methods for the preparation thereof
WO2003057212A1 (en) *	2001-12-26	2003-07-17	Genelabs Technologies, Inc.	Polyamide derivatives possessing antibacterial, antifungal or antitumor activity
US20030129242A1 (en) *	2002-01-04	2003-07-10	Bosch H. William	Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
WO2003059319A1 (en) *	2002-01-14	2003-07-24	Dow Global Technologies Inc.	Drug nanoparticles from template emulsions
ES2485841T3 (es)	2002-02-01	2014-08-14	Ariad Pharmaceuticals, Inc	Compuestos que contienen fósforo y usos de los mismos
PL371416A1 (en) *	2002-02-01	2005-06-13	Pfizer Products Inc.	Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
DK1471887T3 (da)	2002-02-04	2010-06-07	Elan Pharma Int Ltd	Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
US7026465B2 (en) *	2002-02-15	2006-04-11	Corixa Corporation	Fusion proteins of Mycobacterium tuberculosis
MY142238A (en)	2002-03-12	2010-11-15	Tibotec Pharm Ltd	Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
GB0206200D0 (en) *	2002-03-15	2002-05-01	Glaxo Group Ltd	Pharmaceutical compositions
AU2003222027A1 (en) *	2002-03-20	2003-10-08	Elan Pharma International Limited	Fast dissolving dosage forms having reduced friability
EP1800666A1 (en) *	2002-03-20	2007-06-27	Elan Pharma International Limited	Nanoparticulate compositions of angiogenesis inhibitors
ATE385193T1 (de)	2002-03-20	2008-02-15	Mannkind Corp	Inhalationsgerät
US20080220075A1 (en) *	2002-03-20	2008-09-11	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
EP1490030B2 (en) *	2002-03-20	2010-07-14	Elan Pharma International Limited	Nanoparticulate compositions of angiogenesis inhibitors
US20040076586A1 (en) *	2002-03-28	2004-04-22	Reinhard Koening	Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
AU2003221841A1 (en)	2002-04-03	2003-10-27	Celltech R And D, Inc.	Association of polymorphisms in the sost gene region with bone mineral density
US20040038303A1 (en) *	2002-04-08	2004-02-26	Unger Gretchen M.	Biologic modulations with nanoparticles
EP2263650A3 (en)	2002-04-12	2013-12-25	Alkermes Pharma Ireland Limited	Nanoparticulate megestrol formulations
US7101576B2 (en) *	2002-04-12	2006-09-05	Elan Pharma International Limited	Nanoparticulate megestrol formulations
US9101540B2 (en)	2002-04-12	2015-08-11	Alkermes Pharma Ireland Limited	Nanoparticulate megestrol formulations
US20100226989A1 (en) *	2002-04-12	2010-09-09	Elan Pharma International, Limited	Nanoparticulate megestrol formulations
US20040105889A1 (en) *	2002-12-03	2004-06-03	Elan Pharma International Limited	Low viscosity liquid dosage forms
US7582284B2 (en)	2002-04-17	2009-09-01	Nektar Therapeutics	Particulate materials
DE10218109A1 (de) *	2002-04-23	2003-11-20	Jenapharm Gmbh	Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US8501232B2 (en) *	2002-04-23	2013-08-06	Nanotherapeutics, Inc.	Process of forming and modifying particles and compositions produced thereby
US7262208B2 (en) *	2002-04-30	2007-08-28	Elan Pharmaceuticals, Inc.	Hydroxypropyl amides for the treatment of Alzheimer's disease
EP1503737B1 (en) *	2002-05-06	2009-01-07	Elan Pharma International Limited	Nanoparticulate nystatin formulations
PT1517899E (pt)	2002-05-17	2007-11-16	Tibotec Pharm Ltd	¿inibidores da protease do hiv de largo espectro benzisoxazolossulfonamidas substituídas¿
US8313760B2 (en)	2002-05-24	2012-11-20	Angiotech International Ag	Compositions and methods for coating medical implants
RU2341296C2 (ru) *	2002-05-24	2008-12-20	Энджиотек Интернэшнл Аг	Композиции и способы покрытия медицинских имплантатов
US20070264348A1 (en) *	2002-05-24	2007-11-15	Elan Pharma International, Ltd.	Nanoparticulate fibrate formulations
US7763278B2 (en) *	2002-06-10	2010-07-27	Elan Pharma International Ltd.	Nanoparticulate polycosanol formulations and novel polycosanol combinations
EP1531799A1 (en) *	2002-06-10	2005-05-25	Elan Pharma International Limited	Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
AU2003261167A1 (en) *	2002-07-16	2004-02-02	Elan Pharma International, Ltd	Liquid dosage compositions of stable nanoparticulate active agents
GB0216700D0 (en) *	2002-07-18	2002-08-28	Astrazeneca Ab	Process
US20030017208A1 (en) *	2002-07-19	2003-01-23	Francis Ignatious	Electrospun pharmaceutical compositions
AR040588A1 (es) *	2002-07-26	2005-04-13	Schering Corp	Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2002950426A0 (en) *	2002-07-29	2002-09-12	Patrick John Shanahan	Anti microbial oro-dental system
US7838034B2 (en)	2002-07-30	2010-11-23	Grunenthal Gmbh	Intravenous pharmaceutical form of administration
DE10234784A1 (de) *	2002-07-30	2004-02-19	Günenthal GmbH	Intravenös applizierbare, pharmazeutische Darreichungsform
US20040023935A1 (en) *	2002-08-02	2004-02-05	Dey, L.P.	Inhalation compositions, methods of use thereof, and process for preparation of same
US20040028746A1 (en) *	2002-08-06	2004-02-12	Sonke Svenson	Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
US20040028747A1 (en) *	2002-08-06	2004-02-12	Tucker Christopher J.	Crystalline drug particles prepared using a controlled precipitation process
PT1530457E (pt)	2002-08-12	2009-11-06	Bend Res Inc	Composições farmacêuticas de fármacos na forma semi-ordenada e de polímeros
EA010486B1 (ru)	2002-08-14	2008-10-30	Тиботек Фармасьютикалз Лтд.	Замещенные оксиндолсульфонамидные ингибиторы вич-протеазы широкого спектра действия
US7445796B2 (en) *	2002-08-19	2008-11-04	L. Perrigo Company	Pharmaceutically active particles of a monomodal particle size distribution and method
WO2004035032A2 (en) *	2002-08-20	2004-04-29	Neopharm, Inc.	Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) *	2002-08-20	2006-02-09	Neopharm, Inc.	Pharmaceutically active lipid based formulation of irinotecan
UY27939A1 (es)	2002-08-21	2004-03-31	Glaxo Group Ltd	Compuestos
US7268139B2 (en) *	2002-08-29	2007-09-11	Scios, Inc.	Methods of promoting osteogenesis
AU2003276688A1 (en) *	2002-09-02	2004-03-19	Sun Pharmaceutical Industries Limited	Pharmaceutical composition of metaxalone with enhanced oral bioavailability
CA2498207C (en) *	2002-09-11	2012-03-13	Elan Pharma International Ltd.	Gel-stabilized nanoparticulate active agent compositions
WO2004053056A2 (en) *	2002-09-24	2004-06-24	University Of Kentucky Research Foundation	Nanoparticle-based vaccine delivery system containing adjuvant
CA2500908A1 (en) *	2002-10-04	2004-04-22	Elan Pharma International Limited	Gamma irradiation of solid nanoparticulate active agents
US7473432B2 (en) *	2002-10-11	2009-01-06	Idea Ag	NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
EP1562555A2 (en) *	2002-10-24	2005-08-17	Enos Pharmaceuticals, Inc.	Sustained release l-arginine formulations and methods of manufacture and use
US20080145424A1 (en) *	2002-10-24	2008-06-19	Enos Phramaceuticals, Inc.	Sustained release L-arginine formulations and methods of manufacture and use
US7560449B2 (en) *	2002-11-06	2009-07-14	Schering Corporation	Methods and therapeutic combinations for the treatment of demyelination
ES2365012T3 (es) *	2002-11-12	2011-09-20	Elan Pharma International Limited	Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
GB0227443D0 (en) *	2002-11-25	2002-12-31	Glaxo Group Ltd	Pyrimidine derivatives
CA2507484A1 (en)	2002-11-27	2004-06-17	Elan Pharmaceuticals, Inc.	Substituted ureas and carbamates
PT1569912E (pt)	2002-12-03	2015-09-15	Pharmacyclics Llc	Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia
US20050095267A1 (en) *	2002-12-04	2005-05-05	Todd Campbell	Nanoparticle-based controlled release polymer coatings for medical implants
US20040171659A1 (en) *	2002-12-06	2004-09-02	Satyanarayana Medicherla	Methods for treating diabetes
US20040109826A1 (en) *	2002-12-06	2004-06-10	Dey, L.P.	Stabilized albuterol compositions and method of preparation thereof
ATE411010T1 (de) *	2002-12-13	2008-10-15	Jagotec Ag	Topische nanopartikel-spironolacton-formulierung
WO2004058216A2 (en) *	2002-12-17	2004-07-15	Elan Pharma International Ltd.	Milling microgram quantities of nanoparticulate candidate compounds
CA2936612C (en)	2002-12-20	2017-11-21	Celera Corporation	Atf6 polymorphisms associated with myocardial infarction, method of detection and uses thereof
GB0230087D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
GB0230088D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
EP1578421A4 (en) *	2003-01-02	2009-04-22	Femmepharma Holding Co Inc	PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
US9173836B2 (en)	2003-01-02	2015-11-03	FemmeParma Holding Company, Inc.	Pharmaceutical preparations for treatments of diseases and disorders of the breast
KR101110889B1 (ko)	2003-01-06	2012-02-20	코릭사 코포레이션	특정의 아미노알킬 글루코사미나이드 포스페이트 화합물 및그들의 용도
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
WO2004078162A1 (en) *	2003-01-31	2004-09-16	Elan Pharma International Ltd.	Nanoparticulate topiramate formulations
US20040208833A1 (en) *	2003-02-04	2004-10-21	Elan Pharma International Ltd.	Novel fluticasone formulations
GB0302671D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302673D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302672D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
US20100297252A1 (en)	2003-03-03	2010-11-25	Elan Pharma International Ltd.	Nanoparticulate meloxicam formulations
US8512727B2 (en)	2003-03-03	2013-08-20	Alkermes Pharma Ireland Limited	Nanoparticulate meloxicam formulations
EP1606287B1 (en)	2003-03-07	2013-10-02	Merck Sharp & Dohme Corp.	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
WO2004081003A1 (en)	2003-03-07	2004-09-23	Schering Corporation	Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholeterolemia
US7459442B2 (en)	2003-03-07	2008-12-02	Schering Corporation	Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es)	2003-03-07	2009-02-16	Schering Corporation	Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
US20040184995A1 (en) *	2003-03-17	2004-09-23	Yamanouchi Pharmaceutical Co., Ltd.	Novel dry powder inhalation for lung-delivery and manufacturing method thereof
ES2496102T3 (es) *	2003-03-28	2014-09-18	Sigmoid Pharma Limited	Forma de dosificación oral sólida que contiene microcápsulas sin fisuras
BRPI0409100B1 (pt)	2003-04-09	2014-08-05	Osmose Inc	Produto de madeira, e, método para conservar um produto de madeira
US8637089B2 (en)	2003-04-09	2014-01-28	Osmose, Inc.	Micronized wood preservative formulations
US8747908B2 (en)	2003-04-09	2014-06-10	Osmose, Inc.	Micronized wood preservative formulations
US20050054690A1 (en) *	2003-04-21	2005-03-10	Jose Aquino	Phenacyl 2-hydroxy-3-diaminoalkanes
MXPA05011150A (es)	2003-04-21	2005-12-14	Elan Pharm Inc	2-hidroxi-3-diaminoalcanos de benzamida.
MXPA05012467A (es) *	2003-05-19	2006-02-22	Baxter Int	Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
FR2855051B1 (fr) *	2003-05-20	2006-08-25	Oreal	Particules stabilisees en taille par copolymere diacide
WO2004103345A2 (fr) *	2003-05-20	2004-12-02	L'oreal	Particules stabilisees en taille par copolymere diacide
DK1631261T3 (da) *	2003-05-22	2009-11-09	Applied Nanosystems Bv	Fremstilling af små partikler
EP1626742A1 (en) *	2003-05-22	2006-02-22	Elan Pharma International Limited	Sterilization of dispersions of nanoparticulate active agents with gamma radiation
US7459146B2 (en) *	2003-05-30	2008-12-02	3M Innovative Properties Company	Stabilized aerosol dispersions
US7109247B2 (en) *	2003-05-30	2006-09-19	3M Innovative Properties Company	Stabilized particle dispersions containing nanoparticles
DE10325989A1 (de) *	2003-06-07	2005-01-05	Glatt Gmbh	Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
EA015166B1 (ru)	2003-06-16	2011-06-30	Ю-Си-Би Мэньюфэкчуринг, Инк.	Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
JP4971790B2 (ja)	2003-06-17	2012-07-11	オズモウズ，インコーポレーテッド	微粒子状木材保存剤及びその製造方法
GB0314057D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
JP2006527770A (ja) *	2003-06-18	2006-12-07	アストラゼネカアクチボラグ	Ｃｂ１モジュレーターとしての２−置換５，６−ジアリール−ピラジン誘導体
GB0314261D0 (en) *	2003-06-19	2003-07-23	Astrazeneca Ab	Therapeutic agents
US8986736B2 (en) *	2003-06-24	2015-03-24	Baxter International Inc.	Method for delivering particulate drugs to tissues
AU2004249172A1 (en) *	2003-06-24	2004-12-29	Baxter International Inc.	Specific delivery of drugs to the brain
TWI359675B (en) *	2003-07-10	2012-03-11	Dey L P	Bronchodilating β-agonist compositions
US8308682B2 (en)	2003-07-18	2012-11-13	Broncus Medical Inc.	Devices for maintaining patency of surgically created channels in tissue
US20050042177A1 (en) *	2003-07-23	2005-02-24	Elan Pharma International Ltd.	Novel compositions of sildenafil free base
CN100428959C (zh) *	2003-08-06	2008-10-29	卫材R&D管理有限公司	用于制备药物超微粒子的方法和装置
ATE415946T1 (de) *	2003-08-08	2008-12-15	Elan Pharma Int Ltd	Neue metaxalon-zusammensetzungen
US7419996B2 (en) *	2003-08-13	2008-09-02	The University Of Houston	Parenteral and oral formulations of benzimidazoles
GB0319797D0 (en) *	2003-08-26	2003-09-24	Leuven K U Res & Dev	Particle size reduction of poorly soluble drugs
KR20090080143A (ko) *	2003-09-02	2009-07-23	화이자 프로덕츠 인크.	지프라시돈의 지속 방출형 투여 형태
WO2005020933A2 (en) *	2003-09-02	2005-03-10	University Of South Florida	Nanoparticles for drug-delivery
MXPA06002780A (es)	2003-09-11	2006-06-14	Tibotec Pharm Ltd	Inhibidores de entrada del virus de vih.
GB0327723D0 (en) *	2003-09-15	2003-12-31	Vectura Ltd	Pharmaceutical compositions
WO2005030273A2 (en)	2003-09-22	2005-04-07	Baxter International Inc.	High-pressure sterilization to terminally sterilize pharmaceutical preparations and medical products
JP2007521324A (ja) *	2003-09-29	2007-08-02	エノスファーマシューティカルズ，インク．	徐放性ｌ−アルギニン調合物並びにその製造法及び使用法
WO2005032551A1 (en) *	2003-09-30	2005-04-14	Scios Inc.	TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
CA2542499A1 (en) *	2003-10-16	2005-04-28	Teva Pharmaceutical Industries Ltd.	Preparation of candesartan cilexetil
US7338171B2 (en) *	2003-10-27	2008-03-04	Jen-Chuen Hsieh	Method and apparatus for visual drive control
CA2544404A1 (en) *	2003-10-31	2005-06-09	Elan Pharma International Ltd.	Novel nimesulide compositions
US7879360B2 (en) *	2003-11-05	2011-02-01	Elan Pharma International, Ltd.	Nanoparticulate compositions having a peptide as a surface stabilizer
JP2007510659A (ja) *	2003-11-05	2007-04-26	シェーリング　コーポレイション	脂質調節剤および置換アゼチジノンの組み合わせならびに血管状態の処置
AU2004293463A1 (en) *	2003-11-20	2005-06-09	Angiotech International Ag	Implantable sensors and implantable pumps and anti-scarring agents
CZ300438B6 (cs) *	2003-11-25	2009-05-20	Pliva Hrvatska D.O.O.	Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
WO2005053851A1 (en) *	2003-11-26	2005-06-16	E.I. Dupont De Nemours And Company	High pressure media milling system and process of milling particles
WO2005056837A2 (en)	2003-11-26	2005-06-23	Applera Corporation	Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
EP1688169A4 (en) *	2003-11-28	2008-10-01	Mitsubishi Chem Corp	PROCESS FOR PRODUCING FINE PARTICLES OF AN ORGANIC COMPOUND
DK1696898T3 (en) *	2003-12-02	2016-02-22	Univ Ohio State Res Found	ZN2 + -CHELATING DESIGN-BASED SHORT-CHAIN FAT ACIDS AS AN UNKNOWN CLASS OF HISTONDEACETYLASE INHIBITORS
KR100603974B1 (ko)	2003-12-05	2006-07-25	김갑식	고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
EP1708738B1 (en) *	2004-01-12	2016-05-04	MannKind Corporation	A method of reducing serum proinsulin levels in type 2 diabetics
JP2007522129A (ja) *	2004-01-21	2007-08-09	エランファーマシューティカルズ，インコーポレイテッド	アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
EP1713514B1 (en) *	2004-01-28	2021-11-24	Johns Hopkins University	Drugs and gene carrier particles that rapidly move through mucous barriers
EP1713443A2 (en) *	2004-01-29	2006-10-25	Baxter International Inc.	Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
US20050169978A1 (en) *	2004-01-29	2005-08-04	Shu-Wen Fu	Wet-micro grinding
EP1713795A2 (en) *	2004-02-11	2006-10-25	Teva Pharmaceutical Industries Ltd.	Candesartan cilexetil polymorphs
US20050261273A1 (en) *	2004-03-09	2005-11-24	Varghese John	Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
CA2558036A1 (en) *	2004-03-09	2005-09-22	Elan Pharmaceuticals, Inc.	Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007528400A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US20060014737A1 (en) *	2004-03-09	2006-01-19	Varghese John	Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
JP2007528403A (ja) *	2004-03-09	2007-10-11	エランファーマシューティカルズ，インコーポレイテッド	二環式アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
ATE446581T1 (de) *	2004-03-12	2009-11-15	Trinity College Dublin	Magnetoresistives medium
US20080090753A1 (en) *	2004-03-12	2008-04-17	Biodel, Inc.	Rapid Acting Injectable Insulin Compositions
US20050202051A1 (en) *	2004-03-15	2005-09-15	Chinea Vanessa I.	Pharmaceutical vehicle
US20050203482A1 (en) *	2004-03-15	2005-09-15	Chinea Vanessa I.	Pharmaceutical dispensing apparatus and method
TW200602055A (en) *	2004-03-30	2006-01-16	Smithkline Beecham Corp	Spray dried pharmaceutical compositions
HUE028288T2 (en) *	2004-03-31	2016-12-28	Toyama Chemical Co Ltd	Fine dispersion of sparingly soluble drug and process for producing the same
AR048650A1 (es)	2004-05-04	2006-05-10	Tibotec Pharm Ltd	Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
KR100908308B1 (ko) *	2004-05-05	2009-07-17	테바 파마슈티컬 인더스트리즈 리미티드	순도가 높은 칸데사르탄 실렉세틸의 제조
EP2422780A1 (en)	2004-05-07	2012-02-29	Sequoia Pharmaceuticals, Inc.	Resistance-repellent retroviral protease inhibitors
EP2423326B1 (en)	2004-05-07	2014-01-08	Celera Corporation	Genetic polymorphism associated with liver fibrosis methods of detection and uses thereof
US20050252408A1 (en)	2004-05-17	2005-11-17	Richardson H W	Particulate wood preservative and method for producing same
US7622581B2 (en)	2004-05-17	2009-11-24	Tibotec Pharmaceuticals Ltd.	6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agents
BRPI0511267A (pt)	2004-05-17	2007-11-27	Tibotec Pharm Ltd	1,5-diidropirido[3,2-b]indol-2-onas 4-substituìdas
US7316738B2 (en) *	2004-10-08	2008-01-08	Phibro-Tech, Inc.	Milled submicron chlorothalonil with narrow particle size distribution, and uses thereof
CA2564027A1 (en)	2004-05-17	2005-11-24	Tibotec Pharmaceuticals Ltd.	1-heterocyclyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones
AU2005285513B2 (en)	2004-05-25	2011-02-24	Oregon Health And Science University	SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
JP2008500288A (ja) *	2004-05-28	2008-01-10	イメイジノットピーティーワイエルティーディー	経口治療用化合物の供給系
US8216610B2 (en) *	2004-05-28	2012-07-10	Imaginot Pty Ltd.	Oral paracetamol formulations
WO2005117997A1 (en) *	2004-06-01	2005-12-15	The Ohio State University	Ligands having metal binding ability and targeting properties
US8012457B2 (en)	2004-06-04	2011-09-06	Acusphere, Inc.	Ultrasound contrast agent dosage formulation
RU2006144851A (ru) *	2004-06-15	2008-06-20	Бакстер Интернэшнл Инк. (Us)	Применение терапевтических средств ex-vivo в виде твердых микрочастиц
WO2006002088A2 (en) *	2004-06-21	2006-01-05	The Ohio State University Research Foundation	Amino-quinazoline derivatives as antitumor agents
US7385085B2 (en) *	2004-07-09	2008-06-10	Elan Pharmaceuticals, Inc.	Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
AU2005265354A1 (en) *	2004-07-09	2006-01-26	Elan Pharmaceuticals, Inc.	Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
US8409167B2 (en)	2004-07-19	2013-04-02	Broncus Medical Inc	Devices for delivering substances through an extra-anatomic opening created in an airway
JP2008506780A (ja)	2004-07-19	2008-03-06	セレーターファーマスーティカルズ、インク．	活性剤放出のための粒子状構築物
ATE466574T1 (de) *	2004-08-18	2010-05-15	Concordia Pharmaceuticals Inc	Verfahren und zusammensetzungen zur oralen fts- abgabe
EP1791520A2 (en) *	2004-08-19	2007-06-06	Alza Corporation	Controlled release nanoparticle active agent formulation dosage forms and methods
BRPI0514263B8 (pt)	2004-08-20	2021-05-25	Mannkind Corp	método para a síntese de bis-3,6-[4-aminobutil]-2,5-dicetopiperazina n-protegida
GB0418791D0 (en) *	2004-08-23	2004-09-22	Glaxo Group Ltd	Novel process
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
JP2008511644A (ja) *	2004-08-27	2008-04-17	エランファーマシューティカルズ，インコーポレイテッド	エタノール環式アミンアスパラギン酸プロテアーゼ阻害剤を用いて、アミロイドーシスを治療する方法
EP1789018A1 (en)	2004-08-27	2007-05-30	The Dow Chemical Company	Enhanced delivery of drug compositions to treat life threatening infections
EP1797934A4 (en) *	2004-09-07	2009-09-02	Mitsubishi Chem Corp	METHOD FOR PRODUCING A FINE-PARTICULAR SUBSTANCE AND FINE-PARTICULAR SUBSTANCE
US20080171687A1 (en) *	2004-09-16	2008-07-17	Abraxis Bioscience, Inc.	Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs
EP1814530A2 (en) *	2004-09-27	2007-08-08	Sigmoid Biotechnologies Limited	Dihydropyrimidine microcapsule-formulations
US7426948B2 (en) *	2004-10-08	2008-09-23	Phibrowood, Llc	Milled submicron organic biocides with narrow particle size distribution, and uses thereof
WO2006044218A2 (en) *	2004-10-14	2006-04-27	Osmose, Inc.	Micronized wood preservative formulations in organic carriers
KR100651728B1 (ko) *	2004-11-10	2006-12-06	한국전자통신연구원	정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
EP1811961A2 (en) *	2004-11-12	2007-08-01	Idea Ag	Extended surface aggregates in the treatment of skin conditions
US20090155331A1 (en) *	2005-11-16	2009-06-18	Elan Pharma International Limited	Injectable nanoparticulate olanzapine formulations
KR20130030305A (ko) *	2004-11-16	2013-03-26	엘란 파마 인터내셔널 리미티드	주사가능한 나노입자형 올란자핀 제형
US7414031B2 (en) *	2004-11-22	2008-08-19	Genelabs Technologies, Inc.	5-nitro-nucleoside compounds for treating viral infections
UA89513C2 (uk) *	2004-12-03	2010-02-10	Элан Фарма Интернешнл Лтд.	Стабільна композиція з наночастинок ралоксифену гідрохлориду
WO2006062238A1 (ja) *	2004-12-07	2006-06-15	Ajinomoto Co., Inc.	アミノ酸の微粉末及びその懸濁液
WO2006062875A1 (en) *	2004-12-08	2006-06-15	Merck & Co., Inc.	Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
EA013741B1 (ru) *	2004-12-15	2010-06-30	Элан Фарма Интернэшнл Лтд.	Дисперсии наночастиц такролимуса с повышенными растворимостью в воде и биодоступностью, способы их приготовления и применения
EP1837015A1 (en) *	2004-12-17	2007-09-26	Mitsubishi Chemical Corporation	Novel core-shell structure
US20060159767A1 (en) *	2004-12-22	2006-07-20	Elan Pharma International Limited	Nanoparticulate bicalutamide formulations
CN104083342A (zh) *	2004-12-31	2014-10-08	伊休蒂卡有限公司	纳米微粒组合物及其合成方法
AU2005321751B2 (en) *	2004-12-31	2012-04-05	Iceutica Pty Ltd	Nanoparticle composition and methods for synthesis thereof
AU2012201630B8 (en) *	2004-12-31	2014-03-06	Iceutica Pty Ltd	NanoParticle Composition(s) and Method for Synthesis Thereof
EP1835890A2 (en) *	2005-01-06	2007-09-26	Elan Pharma International Limited	Nanoparticulate candesartan formulations
CN101102740A (zh) *	2005-01-07	2008-01-09	卫材R&D管理有限公司	药用组合物以及其制备方法
WO2006087919A1 (ja) *	2005-01-28	2006-08-24	Takeda Pharmaceutical Company Limited	難水溶性物質含有微細化組成物
ES2265262B1 (es) *	2005-01-31	2008-03-01	Activery Biotech, S.L.(Titular Al 50%)	Procedimiento para la obtencion de sistemas micro- y nanodispersos.
CN101137668B (zh)	2005-02-08	2011-08-17	研究发展基金会	与可溶性G蛋白偶联受体（sGPCR）有关的组合物与方法
CA2597716A1 (en) *	2005-02-15	2006-08-24	Elan Pharma International Limited	Aerosol and injectable formulations of nanoparticulate benzodiazepine
WO2006093987A1 (en) *	2005-02-28	2006-09-08	Genelabs Technologies, Inc.	Tricyclic-nucleoside compounds for treating viral infections
AU2005100176A4 (en) *	2005-03-01	2005-04-07	Gym Tv Pty Ltd	Garbage bin clip
CA2598288A1 (en) *	2005-03-03	2006-09-14	Elan Pharma International Limited	Nanoparticulate compositions of heterocyclic amide derivatives
WO2006099121A2 (en) *	2005-03-10	2006-09-21	Elan Pharma International Limited	Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
EP1856296A2 (en)	2005-03-11	2007-11-21	Applera Corporation	Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
CN101175480A (zh) *	2005-03-16	2008-05-07	伊兰制药国际有限公司	纳米微粒白三烯受体拮抗剂/皮质类固醇制剂
EA200701997A1 (ru) *	2005-03-17	2008-02-28	Элан Фарма Интернэшнл Лтд.	Композиция из наночастиц бисфосфоната
KR20070121786A (ko) *	2005-03-23	2007-12-27	엘란 파마 인터내셔널 리미티드	나노입자형 코르티코스테로이드 및 항히스타민 제제
US20070224282A1 (en) *	2005-03-28	2007-09-27	Toyama Chemical Co., Ltd.	Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
BRPI0609547A2 (pt)	2005-03-31	2011-10-18	Glaxosmithkline Biolog Sa	composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
TW200710091A (en)	2005-04-11	2007-03-16	Tibotec Pharm Ltd	(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
CA2603084A1 (en) *	2005-04-12	2006-10-19	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising cyclosporine
WO2006110811A1 (en) *	2005-04-12	2006-10-19	Elan Pharma International Limited	Nanoparticulate quinazoline derivative formulations
US20060246141A1 (en) *	2005-04-12	2006-11-02	Elan Pharma International, Limited	Nanoparticulate lipase inhibitor formulations
US20080305161A1 (en) *	2005-04-13	2008-12-11	Pfizer Inc	Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
ES2326354B1 (es) *	2005-04-13	2010-07-08	Elan Pharma International Limited	Composiciones de liberacion controlada y nanoparticuladas que comprenden derivados de prostaglandina.
MX2007012103A (es) *	2005-04-13	2007-11-20	Pfizer Prod Inc	Formulaciones deposito inyectables y metodos para proporcionar una liberacion sostenida de composiciones de nanoparticulas.
DE502006005846D1 (de) *	2005-04-13	2010-02-25	Abbott Gmbh & Co Kg	Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
ITMI20050739A1 (it) *	2005-04-22	2006-10-23	Effebi Spa	Piastrina di connsessione valvola-attuatore
WO2006116557A1 (en) *	2005-04-25	2006-11-02	Genelabs Technologies, Inc.	Nucleoside compounds for treating viral infections
PL2426141T3 (pl)	2005-04-29	2015-02-27	Glaxosmithkline Biologicals Sa	Sposób profilaktyki lub leczenia zakażenia m. tuberculosis
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
US7592429B2 (en) *	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
EP1888037A2 (en) *	2005-05-10	2008-02-20	Elan Pharma International Limited	Nanoparticulate clopidogrel formulations
WO2006132752A1 (en) *	2005-05-10	2006-12-14	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising vitamin k2
JP2008540550A (ja) *	2005-05-10	2008-11-20	エラン・ファルマ・インターナショナル・リミテッド	ビタミンｋ２を含むナノ粒子および制御放出組成物
US20070082055A1 (en) *	2005-05-10	2007-04-12	Ziv Kurgan	Stable micronized candesartan cilexetil and methods for preparing thereof
WO2008010784A1 (en) *	2005-05-16	2008-01-24	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising a cephalosporin
CA2611506A1 (en) *	2005-05-23	2006-11-23	Elan Pharma International Limited	Nanoparticulate and controlled release compositions comprising a platelet aggregation inhibitor
AU2006309295B2 (en) *	2005-06-03	2012-04-26	Elan Pharma International Limited	Nanoparticulate acetaminophen formulations
US20060275372A1 (en)	2005-06-03	2006-12-07	Elan Pharma International Limited	Nanoparticulate imatinib mesylate formulations
WO2006133045A1 (en) *	2005-06-03	2006-12-14	Elan Pharma International, Limited	Nanoparticulate benidipine compositions
MX2007015511A (es) *	2005-06-07	2008-03-06	Univ Ramot	Sales novedosas de farmacos sicotropicos conjugados y procesos para prepararlas.
EP1954253A4 (en) *	2005-06-08	2011-07-27	Elan Pharma Int Ltd	NANOTEILIC AND CONTROLLED RELEASED COMPOSITIONS WITH CEFDITORS
WO2006135689A2 (en) *	2005-06-09	2006-12-21	Elan Pharma International, Limited	Nanoparticulate ebastine formulations
BRPI0611626A2 (pt) *	2005-06-13	2010-09-21	Elan Pharma Int Ltd	formulações da combinação de nanopartìculas de clopidogrel e aspirina
WO2006138421A2 (en) *	2005-06-15	2006-12-28	Elan Pharma International Limited	Nanoparticulate azelnidipine formulations
KR20080024206A (ko) *	2005-06-20	2008-03-17	엘란 파마 인터내셔널 리미티드	아릴-헤테로시클릭 화합물을 함유하는 나노입자형 조절방출 조성물
EP1901713A2 (en) *	2005-06-22	2008-03-26	Elan Pharma International Limited	Nanoparticulate megestrol formulations
WO2006138744A2 (en) *	2005-06-24	2006-12-28	Genelabs Technologies, Inc.	Heteroaryl derivatives for treating viruses
US20090028950A1 (en) *	2005-06-29	2009-01-29	Mitsubishi Chemical Corporation	Granule dispersion composition, process for producing the same, and granular material and medicine
BRPI0612848B8 (pt) *	2005-06-29	2021-05-25	Dsm Ip Assets Bv	composição de nanopartículas de isoflavona, processo para a produção da mesma e seu uso, composição farmacêutica, composição cosmética, e produto nutricional
WO2007008537A2 (en) *	2005-07-07	2007-01-18	Elan Pharma International, Limited	Nanoparticulate clarithromycin formulations
EP1922150A1 (en) *	2005-07-07	2008-05-21	Nanotherapeutics, Inc.	Process for milling and preparing powders and compositions produced thereby
US20070298109A1 (en) *	2005-07-07	2007-12-27	The Trustees Of The University Of Pennsylvania	Nano-scale devices
US20100183725A1 (en) *	2005-07-15	2010-07-22	Map Pharmaceuticals, Inc.	Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
WO2007016597A2 (en) *	2005-07-29	2007-02-08	The Regents Of The University Of California	Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
PE20070232A1 (es) *	2005-08-10	2007-04-09	Novartis Ag	Composicion que comprende microparticulas de 7-terbutoxi-imino-metil-campotecina
WO2007017513A2 (en) *	2005-08-10	2007-02-15	Novartis Ag	Formulations for 7-(t-butoxy)iminomethyl camptothecin
GB0516549D0 (en) *	2005-08-12	2005-09-21	Sulaiman Brian	Milling system
AU2006280511A1 (en) *	2005-08-12	2007-02-22	Astrazeneca Ab	Process
BRPI0615265A8 (pt)	2005-08-31	2018-03-06	Abraxis Bioscience Llc	composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
CN101291658B (zh) *	2005-08-31	2014-04-16	阿布拉科斯生物科学有限公司	用于制备稳定性增加的水难溶性药物的组合物和方法
CA2621800A1 (en) *	2005-09-06	2007-03-15	Astellas Pharma Inc.	Fine particles of poorly soluble drug having enteric base material adsorbed on the surface thereof
JP2009507925A (ja) *	2005-09-13	2009-02-26	エランファーマインターナショナルリミテッド	ナノ粒子タダラフィル製剤
AU2006290870B2 (en)	2005-09-14	2013-02-28	Mannkind Corporation	Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces
EP1933814A2 (en)	2005-09-15	2008-06-25	Elan Pharma International Limited	Nanoparticulate aripiprazole formulations
US7799530B2 (en)	2005-09-23	2010-09-21	Celera Corporation	Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US7713929B2 (en)	2006-04-12	2010-05-11	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) *	2005-09-29	2007-04-19	Biodel, Inc.	Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US8084420B2 (en) *	2005-09-29	2011-12-27	Biodel Inc.	Rapid acting and long acting insulin combination formulations
WO2007041079A2 (en) *	2005-09-30	2007-04-12	Alza Corporation	Banded controlled release nanoparticle active agent formulation dosage forms and methods
AU2006302078B2 (en)	2005-10-07	2012-11-22	Exelixis, Inc.	Pyridopyrimidinone inhibitors of PI3Kalpha
SI1931645T1 (sl)	2005-10-07	2014-09-30	Exelixis, Inc.	N-(3-amino-kvinoksalin-2-YL)-sulfonamid-derivati in uporaba le teh kot fosfatidilinositol-3-kinaze-inhibitorji
EP1937638A1 (en) *	2005-10-12	2008-07-02	Elan Pharmaceuticals Inc.	Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
WO2007047305A1 (en) *	2005-10-12	2007-04-26	Elan Pharmaceuticals, Inc.	Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
US7695911B2 (en)	2005-10-26	2010-04-13	Celera Corporation	Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
DE102005053862A1 (de) *	2005-11-04	2007-05-10	Pharmasol Gmbh	Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
CA2631082C (en)	2005-11-23	2015-02-03	Board Of Regents Of The University Of Texas System	Oncogenic ras-specific cytotoxic compound and methods of use thereof
MX336930B (es)	2005-11-28	2016-02-05	Marinus Pharmaceuticals	Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
EP3263117A1 (en) *	2005-11-28	2018-01-03	Imaginot Pty Ltd.	Oral therapeutic compound delivery system
US20120121653A1 (en) *	2005-12-02	2012-05-17	Elan Pharma International Limited	Novel mometasone compositions and methods of making and using the same
RU2008128452A (ru) *	2005-12-12	2010-01-20	Дженелабс Текнолоджис, Инк. (Us)	Соединения n-(6-членных арил)-амидов, фармацевтическая композиция с противовирусной активностью на их основе, способ лечения или профилактики вирусной инфекции с их помощью и способ их получения
US20070185066A1 (en) *	2005-12-20	2007-08-09	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) *	2005-12-20	2007-07-12	Verus Pharmaceuticals, Inc.	Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) *	2005-12-20	2007-08-02	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) *	2005-12-20	2007-10-25	Verus Pharmaceuticals, Inc.	Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) *	2005-12-20	2007-08-23	Verus Pharmaceuticals, Inc.	Methods and systems for the delivery of corticosteroids
ES2684821T3 (es)	2005-12-29	2018-10-04	Lexicon Pharmaceuticals, Inc.	Derivados de aminoácidos multicíclicos y métodos de su uso
US20090081157A1 (en)	2006-01-09	2009-03-26	Richard Syd Kornbluth	Immunostimulatory Combinations for Vaccine Adjuvants
UA96436C2 (ru)	2006-01-20	2011-11-10	Тиботек Фармасьютикелз Лтд.	Долгосрочное лечение вич-инфекции
CA2642641A1 (en) *	2006-02-15	2007-08-23	Tika Laekemedel Ab	Stable corticosteroid mixtures
JP5599975B2 (ja)	2006-02-22	2014-10-01	マンカインドコーポレイション	ジケトピペラジン及び活性薬剤を含有する微粒子の製剤特性の改善方法
JP2009527504A (ja) *	2006-02-23	2009-07-30	イオメディックススリープインターナショナルエスアールエル	良質な睡眠の誘導および維持のための組成物および方法
US7649098B2 (en)	2006-02-24	2010-01-19	Lexicon Pharmaceuticals, Inc.	Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) *	2006-02-28	2013-02-05	Alkermes Pharma Ireland Limited	Nanoparticulate carverdilol formulations
US20090099175A1 (en) *	2006-03-01	2009-04-16	Arrington Mark P	Phosphodiesterase 10 inhibitors
US11311477B2 (en)	2006-03-07	2022-04-26	Sgn Nanopharma Inc.	Ophthalmic preparations
US20070264349A1 (en) *	2006-03-07	2007-11-15	Novavax, Inc.	Nano-structured compositions and methods of making and using the same
US10137083B2 (en)	2006-03-07	2018-11-27	SGN Nanopharma Inc	Ophthalmic preparations
EP1993513A4 (en) *	2006-03-14	2012-06-27	Merck Sharp & Dohme	METHOD AND DEVICE FOR PREPARING CRYSTALLINE ORGANIC MICROPARTICLE COMPOSITIONS USING MICROMATES AND CRYSTALLIZING MICROSAMEN AND THEIR USE
AU2007233683A1 (en)	2006-04-03	2007-10-11	Janssen R&D Ireland	HIV inhibiting 3,4-dihydro-imidazo[4,5-b]pyridin-5-ones
US7718609B2 (en) *	2006-04-12	2010-05-18	Biodel Inc.	Rapid acting and long acting insulin combination formulations
US20080299210A1 (en) *	2006-04-13	2008-12-04	Min Wei	Stable nanosized amorphous drug
MX2008013427A (es)	2006-04-19	2008-11-04	Novartis Ag	Compuestos de benzoxazole y benzotiazole sustituidos-6-0 y metodos para inhibir la señalizacion csf-1r.
JP2007306950A (ja) *	2006-05-15	2007-11-29	Osaka Univ	薬効成分ナノ粒子分散液の製造方法
US20070275052A1 (en) *	2006-05-24	2007-11-29	Glenmark Pharmaceuticals Limited	Pharmaceutical compositions containing sterol inhibitors
BRPI0712130A2 (pt)	2006-05-30	2012-01-17	Elan Pharma Int Ltd	formulações de posaconazol em nanopartìculas
JP5406022B2 (ja) *	2006-06-12	2014-02-05	スミスアンドネフューインコーポレーテッド	脛骨切除システム、方法、及び装置
PL2037914T3 (pl) *	2006-06-14	2014-04-30	Intervet Int Bv	Zawiesina zawierająca karbaminian benzoimidazolu i polisorbat
EA021700B1 (ru)	2006-06-23	2015-08-31	Тиботек Фармасьютикалз Лтд.	Фармацевтическая композиция, содержащая 4-[[4-[[4-(2-цианоэтенил)-2,6-диметилфенил]амино]-2-пиримидинил]амино]бензонитрил (тмс278) в форме суспензии микро- или наночастиц, способ ее получения и ее применение для длительного лечения или профилактики вич-инфекции
US20080181957A1 (en) *	2006-06-23	2008-07-31	Min Wei	Increased amorphous stability of poorly water soluble drugs by nanosizing
CA2656277A1 (en) *	2006-06-26	2008-01-03	Mutual Pharmaceutical Company, Inc.	Active agent formulations, methods of making, and methods of use
WO2008002583A1 (en)	2006-06-28	2008-01-03	Amgen Inc.	Glycine transporter-1 inhibitors
CA2653384C (en)	2006-06-30	2017-03-14	Iceutica Pty Ltd	Methods for the preparation of biologically active compounds in nanoparticulate form
CN101568330A (zh) *	2006-06-30	2009-10-28	伊休蒂卡有限公司	用于制备纳米粒形式的生物活性化合物的方法
EP2049084A2 (en) *	2006-07-10	2009-04-22	Elan Pharma International Limited	Nanoparticulate sorafenib formulations
EP2051735B1 (en) *	2006-07-17	2012-08-29	Ramot, at Tel Aviv University Ltd.	Conjugates comprising a psychotropic drug or a gaba agonist and an organic acid and their use treating pain and other cns disorders
RU2009105837A (ru) *	2006-07-20	2010-08-27	СмитКлайн Бичем Копэрейшн (US)	Полициклические противовирусные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусной инфекции с ее помощью и названные соединения для изготовления лекарственных средств
KR20090027734A (ko) *	2006-07-27	2009-03-17	(주)아모레퍼시픽	난용성 약물의 나노입자를 포함하는 분말의 제조방법
EP2054397B1 (en)	2006-08-16	2015-10-07	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Small molecule inhibitors of kynurenine-3-monooxygenase
EP2420494B1 (en)	2006-08-16	2014-10-08	The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone	Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase
WO2008026216A2 (en) *	2006-08-28	2008-03-06	Hetero Drugs Limited	Process for purification of aprepitant
CL2007002567A1 (es)	2006-09-08	2008-02-01	Amgen Inc	Proteinas aisladas de enlace a activina a humana.
CA2663003C (en) *	2006-09-08	2018-02-13	Justin Hanes	Compositions and methods for enhancing transport through mucus
US8080645B2 (en)	2007-10-01	2011-12-20	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection/transport compositions and methods
US9481912B2 (en)	2006-09-12	2016-11-01	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8097419B2 (en)	2006-09-12	2012-01-17	Longhorn Vaccines & Diagnostics Llc	Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
WO2008085556A2 (en)	2006-09-12	2008-07-17	University Of South Florida	Surfactant-free nanoparticles for drug delivery
AR063704A1 (es) *	2006-09-14	2009-02-11	Makhteshim Chem Works Ltd	Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
EP2061583B1 (en) *	2006-09-14	2019-04-10	Yissum Research Development Company, of The Hebrew University of Jerusalem	Organic nanoparticles obtained from microemulsions by solvent evaporation
CL2007002689A1 (es)	2006-09-18	2008-04-18	Vitae Pharmaceuticals Inc	Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
BRPI0716890A2 (pt) *	2006-09-22	2013-10-22	Labopharm Inc	Composição, e, método de produção de uma composição, de administração de um agente farmaceuticamente ativo insolúvel em água a um mamífero, e de tratamento de câncer em um mamífero
CA2915679C (en)	2006-10-20	2017-12-12	Celera Corporation	Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
CN1946120B (zh) *	2006-10-20	2010-05-12	华为技术有限公司	实现话单关联的方法及系统
US8946200B2 (en) *	2006-11-02	2015-02-03	Southwest Research Institute	Pharmaceutically active nanosuspensions
US20100036091A1 (en) *	2006-11-10	2010-02-11	Amgen Inc.	Antibody-based diagnostics and therapeutics
EP2094731A2 (en) *	2006-11-10	2009-09-02	UCB Pharma S.A.	Anti human sclerostin antibodies
CA2669392C (en) *	2006-11-17	2016-05-10	Abbott Gmbh & Co. Kg	Nanocrystals for use in topical cosmetic formulations and method of production thereof
WO2009070744A1 (en)	2007-11-28	2009-06-04	Sequoia Pharmaceuticals, Inc.	Compositions and methods for inhibiting cytochrome p450 2d6
KR20080047956A (ko) *	2006-11-27	2008-05-30	주식회사 엠디바이오알파	발기부전의 치료 및 예방을 위한 약제 조성물
BRPI0717721A2 (pt)	2006-11-28	2013-10-29	Marinus Pharmaceuticals	"partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
WO2008070072A2 (en) *	2006-12-01	2008-06-12	Mutual Pharmaceutical Company, Inc.	Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) *	2006-12-01	2009-01-29	Kristin Arnold	Carvedilol forms, compositions, and methods of preparation thereof
EP1938800A1 (en)	2006-12-06	2008-07-02	Ranbaxy Laboratories Limited	Sirolimus nanodispersion
UA99270C2 (en)	2006-12-12	2012-08-10	Лексикон Фармасьютикалз, Инк.	4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
WO2008083158A2 (en) *	2006-12-26	2008-07-10	Femmepharma Holding Company, Inc.	Topical administration of danazol
DE102007001473A1 (de)	2007-01-08	2008-07-10	Andreas Lemke	Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
TW200848039A (en) *	2007-02-09	2008-12-16	Astrazeneca Ab	Pharmaceutical compositions
JP2010517759A (ja) *	2007-02-09	2010-05-27	アストラゼネカ・アクチエボラーグ	水性媒体中における固体非晶質サブミクロン粒子の安定な分散体を製造する方法
ES2538082T3 (es)	2007-02-11	2015-06-17	Map Pharmaceuticals Inc	Método de administración terapéutica de DHE para permitir el rápido alivio de migraña mientras que se minimiza el perfil de efectos secundarios
US20100151035A1 (en) *	2007-03-13	2010-06-17	Sandoz Ag	Pharmaceutical compositions of poorly soluble drugs
AR065720A1 (es)	2007-03-14	2009-06-24	Tibotec Pharm Ltd	Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
CA2680796A1 (en)	2007-03-14	2008-09-18	Exelixis, Inc.	Inhibitors of the hedgehog pathway
ES2400964T3 (es)	2007-04-04	2013-04-15	Sigmoid Pharma Limited	Composiciones famacéuticas de ciclosporina
WO2008124522A2 (en) *	2007-04-04	2008-10-16	Biodel, Inc.	Amylin formulations
TWI405590B (zh)	2007-04-06	2013-08-21	Activus Pharma Co Ltd	微粉碎化有機化合物粒子之製法
PL2191001T4 (pl)	2007-04-09	2017-01-31	University Of Florida Research Foundation, Inc.	Kompozycje wektora RAAV mające białka kapsydu zmodyfikowane tyrozyną i sposoby ich zastosowania
CA2942083C (en)	2007-04-26	2019-01-29	Sigmoid Pharma Limited	Manufacture of multiple minicapsules
US20100215737A1 (en) *	2007-05-01	2010-08-26	Ivan Coulter	Combination pharmaceutical compositions
WO2008135828A2 (en)	2007-05-03	2008-11-13	Pfizer Products Inc.	Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en)	2007-05-03	2014-04-22	Bend Research, Inc.	Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
US20080279784A1 (en) *	2007-05-07	2008-11-13	Questcor Pharmaceuticals, Inc.	Nasal administration of benzodiazepines
US8530463B2 (en) *	2007-05-07	2013-09-10	Hale Biopharma Ventures Llc	Multimodal particulate formulations
MX2009012679A (es)	2007-05-21	2009-12-11	Novartis Ag	Inhibidores de csf-1r, composiciones y metodos de uso.
US8426467B2 (en)	2007-05-22	2013-04-23	Baxter International Inc.	Colored esmolol concentrate
US8722736B2 (en)	2007-05-22	2014-05-13	Baxter International Inc.	Multi-dose concentrate esmolol with benzyl alcohol
CA2724951C (en) *	2007-05-31	2021-09-07	The Administrators Of The Tulane Educational Fund	Method of forming stable functionalized nanoparticles
EP2162120B1 (en)	2007-06-04	2016-05-04	Bend Research, Inc	Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en)	2007-06-04	2008-12-11	Pfizer Products Inc.	Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
RU2327457C1 (ru) *	2007-06-26	2008-06-27	Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи")	Лекарственное средство на основе рифабутина, препарат противомикробного действия, содержащий наночастицы, и способ его получения
EP2170384B1 (en)	2007-07-02	2016-04-13	Etubics Corporation	Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
WO2009008391A1 (ja)	2007-07-06	2009-01-15	M.Technique Co., Ltd.	生体摂取物微粒子の製造方法、生体摂取物微粒子及びこれを含有する分散体、医薬組成物
WO2009007441A2 (en)	2007-07-12	2009-01-15	Tibotec Pharmaceuticals Ltd.	Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
EP2178519B1 (en)	2007-07-13	2012-04-25	Bend Research, Inc.	Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
EA201000201A1 (ru) *	2007-08-10	2010-12-30	ГЛАКСОСМИТКЛАЙН ЭлЭлСи	Азотсодержащие бициклические химические вещества для лечения вирусных инфекций
US9683256B2 (en)	2007-10-01	2017-06-20	Longhorn Vaccines And Diagnostics, Llc	Biological specimen collection and transport system
US11041215B2 (en)	2007-08-24	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en)	2007-08-27	2018-06-26	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
AU2008293504B2 (en)	2007-08-27	2012-04-12	Longhorn Vaccines & Diagnostics, Llc	Immunogenic compositions and methods
WO2009029729A1 (en) *	2007-08-31	2009-03-05	Genelabs Technologies, Inc.	Amino tricyclic-nucleoside compounds, compositions, and methods of use
EP2197429B9 (en) *	2007-09-03	2016-10-26	Nanotherapeutics, Inc.	Particulate compositions for delivery of poorly soluble drugs
US20090068266A1 (en) *	2007-09-11	2009-03-12	Raheja Praveen	Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090130210A1 (en) *	2007-09-11	2009-05-21	Raheja Praveen	Pharmaceutical compositions of sirolimus
US8232413B2 (en) *	2007-09-12	2012-07-31	Merck Sharp & Dohme Corp.	Process for the production of a crystalline glucagon receptor antagonist compound
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
CA2700426C (en)	2007-09-25	2017-10-31	Galia Temtsin Krayz	Compositions comprising lipophilic active compounds and method for their preparation
AU2008343745B2 (en)	2007-10-01	2012-05-10	Longhorn Vaccines & Diagnostics Llc	Biological specimen collection and transport system and methods of use
US11041216B2 (en)	2007-10-01	2021-06-22	Longhorn Vaccines And Diagnostics, Llc	Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
EP2217225A4 (en) *	2007-10-11	2012-12-19	Mazence Inc	PHARMACEUTICAL COMPOSITION WITH MICRONIZED PARTICLES OF A NAPHTHOCHINONE BASED COMPOUND
CA2702261A1 (en) *	2007-10-12	2009-04-16	Map Pharmaceuticals, Inc.	Inhalation drug delivery
US9206233B2 (en)	2007-10-19	2015-12-08	University of Pittsburgh—of the Commonwealth System of Higher Education	Templates for controlling synthesis of nanoparticles into discrete assemblies
US8785396B2 (en)	2007-10-24	2014-07-22	Mannkind Corporation	Method and composition for treating migraines
US8642062B2 (en)	2007-10-31	2014-02-04	Abbott Cardiovascular Systems Inc.	Implantable device having a slow dissolving polymer
US8039212B2 (en)	2007-11-05	2011-10-18	Celera Corporation	Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
JP2011503232A (ja)	2007-11-20	2011-01-27	ザブリガムアンドウィメンズホスピタルインコーポレイテッド	免疫応答の調節
US8598165B2 (en)	2007-11-26	2013-12-03	University Of Kansas	Morpholines as selective inhibitors of cytochrome P450 2A13
US9233078B2 (en)	2007-12-06	2016-01-12	Bend Research, Inc.	Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
US9724362B2 (en)	2007-12-06	2017-08-08	Bend Research, Inc.	Pharmaceutical compositions comprising nanoparticles and a resuspending material
KR100961880B1 (ko) *	2007-12-12	2010-06-09	중앙대학교 산학협력단	밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
US20090238867A1 (en) *	2007-12-13	2009-09-24	Scott Jenkins	Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
EP2628486A3 (en) *	2007-12-14	2013-10-30	Amgen, Inc.	Method for treating bone fracture with anti-sclerostin antibodies
CA2710122A1 (en)	2007-12-20	2009-07-02	Novartis Ag	Thiazole derivatives used as pi 3 kinase inhibitors
US20090197856A1 (en) *	2007-12-21	2009-08-06	Genelabs Technologies, Inc.	Antiviral compounds
US20100054981A1 (en) *	2007-12-21	2010-03-04	Board Of Regents, The University Of Texas System	Magnetic nanoparticles, bulk nanocomposite magnets, and production thereof
US9242295B2 (en)	2007-12-21	2016-01-26	The Univeristy Of Texas At Arlington	Bulk nanocomposite magnets and methods of making bulk nanocomposite magnets
KR101405823B1 (ko) *	2007-12-24	2014-06-12	주식회사 케이티앤지생명과학	녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) *	2007-12-28	2009-07-02	주식회사 머젠스	신장질환의 치료 및 예방을 위한 약제 조성물
US20090175840A1 (en) *	2008-01-04	2009-07-09	Biodel, Inc.	Insulin formulations for insulin release as a function of tissue glucose levels
IL188647A0 (en)	2008-01-08	2008-11-03	Orina Gribova	Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US20090202649A1 (en) *	2008-02-06	2009-08-13	Subhash Gore	Fenofibrate formulations
WO2009101616A1 (en)	2008-02-11	2009-08-20	Ramot At Tel Aviv University Ltd.	Novel conjugates for treating neurodegenerative diseases and disorders
US20090221620A1 (en)	2008-02-20	2009-09-03	Celera Corporation	Gentic polymorphisms associated with stroke, methods of detection and uses thereof
CA2716348C (en)	2008-02-21	2017-04-04	Sequoia Pharmaceuticals, Inc.	Diamide inhibitors of cytochrome p450
EP2254555A4 (en) *	2008-02-27	2013-10-09	Reddys Lab Ltd Dr	APREPITANT FORMS WITH INCREASED SOLUBILITY AND PHARMACEUTICAL COMPOSITIONS FROM THEREOF
CN101965195A (zh)	2008-03-05	2011-02-02	巴克斯特国际公司	用于药物投送的组合物和方法
US8404850B2 (en) *	2008-03-13	2013-03-26	Southwest Research Institute	Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
CA2715422A1 (en) *	2008-03-21	2009-09-24	Elan Pharma International Limited	Compositions for site-specific delivery of imatinib and methods of use
CA2756690C (en)	2008-03-28	2016-08-16	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
HU230862B1 (hu) *	2008-04-28	2018-10-29	DARHOLDING Vagyonkezelő Kft	Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
EP2285352A2 (en) *	2008-05-13	2011-02-23	Dr. Reddy's Laboratories Ltd.	Atorvastatin compositions
US8173621B2 (en)	2008-06-11	2012-05-08	Gilead Pharmasset Llc	Nucleoside cyclicphosphates
US20090311335A1 (en) *	2008-06-12	2009-12-17	Scott Jenkins	Combination of a triptan and an nsaid
US8499757B2 (en)	2008-06-13	2013-08-06	Mannkind Corporation	Dry powder inhaler and system for drug delivery
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
GB2460915B (en) *	2008-06-16	2011-05-25	Biovascular Inc	Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
ES2904623T3 (es)	2008-06-20	2022-04-05	Mannkind Corp	Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación
EP2310525B1 (en)	2008-07-09	2014-02-26	Celera Corporation	Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
US20100151037A1 (en) *	2008-08-07	2010-06-17	Yivan Jiang	Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
DE102008037025C5 (de)	2008-08-08	2016-07-07	Jesalis Pharma Gmbh	Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
US8722706B2 (en) *	2008-08-15	2014-05-13	Southwest Research Institute	Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
PL2334378T3 (pl)	2008-08-19	2014-09-30	Xenoport Inc	Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
US9700525B2 (en)	2008-08-20	2017-07-11	Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College	Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
EP3574921A1 (en)	2008-09-10	2019-12-04	BioChemics, Inc.	Ibuprofen for topical administration
TWI580441B (zh) *	2008-09-19	2017-05-01	愛爾康研究有限公司	穩定的藥學次微米懸浮液及其形成方法
ES2467676T3 (es) *	2008-09-19	2014-06-12	Activus Pharma Co., Ltd.	Polvo de un compuesto orgánico combinado para uso médico, método para producir el mismo y suspensión del mismo
GB0818403D0 (en) *	2008-10-08	2008-11-12	Univ Leuven Kath	Aqueous electrophoretic deposition
US8309134B2 (en) *	2008-10-03	2012-11-13	Southwest Research Institute	Modified calcium phosphate nanoparticle formation
EP2334845A2 (en) *	2008-10-06	2011-06-22	Katholieke Universiteit Leuven K.U. Leuven R&D	Functional layers of biomolecules and living cells, and a novel system to produce such
US20100098770A1 (en) *	2008-10-16	2010-04-22	Manikandan Ramalingam	Sirolimus pharmaceutical formulations
US8277697B2 (en) *	2008-10-29	2012-10-02	Global Oled Technology Llc	Color filter element with improved colorant dispersion
RU2431495C2 (ru) *	2008-11-19	2011-10-20	Общество с ограниченной ответственностью "Биолит"	Жаропонижающее средство и способ его получения
US20100160369A1 (en)	2008-12-04	2010-06-24	Exelixis, Inc.	S1P1 Agonists and Methods of Making And Using
CN102307576A (zh)	2008-12-15	2012-01-04	班纳制药公司	用于增强水不溶性活性剂的释放和吸收的方法
CA2746307C (en)	2008-12-17	2013-11-19	Amgen Inc.	Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
WO2010075517A2 (en) *	2008-12-23	2010-07-01	Pharmasset, Inc.	Nucleoside analogs
AR074897A1 (es)	2008-12-23	2011-02-23	Pharmasset Inc	Fosforamidatos de nucleosidos
WO2010075554A1 (en)	2008-12-23	2010-07-01	Pharmasset, Inc.	Synthesis of purine nucleosides
US20100159010A1 (en) *	2008-12-24	2010-06-24	Mutual Pharmaceutical Company, Inc.	Active Agent Formulations, Methods of Making, and Methods of Use
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
AU2009334794B2 (en)	2009-01-02	2014-12-04	Bgp Products Ireland Limited	Novel use of fibrates
WO2010080754A2 (en)	2009-01-06	2010-07-15	Pharmanova, Inc.	Nanoparticle pharmaceutical formulations
US11304960B2 (en)	2009-01-08	2022-04-19	Chandrashekar Giliyar	Steroidal compositions
AU2010206724A1 (en)	2009-01-22	2011-07-28	Nanotherapeutics, Inc.	Process for preparing particles of opioids and compositions produced thereby
AR075180A1 (es) *	2009-01-29	2011-03-16	Novartis Ag	Formulaciones orales solidas de una pirido-pirimidinona
US20110294901A1 (en)	2009-01-30	2011-12-01	Shigeru Chikase	Finely pulverized pharmaceutical composition
EP2393488B1 (en)	2009-02-06	2019-06-19	University Of Southern California	Therapeutic compositions comprising monoterpenes
WO2010091164A1 (en)	2009-02-06	2010-08-12	Exelixis, Inc.	Inhibitors of glucosylceramide synthase
WO2010091104A1 (en)	2009-02-06	2010-08-12	Exelixis, Inc.	Glucosylceramide synthase inhibitors
US20100204265A1 (en) *	2009-02-09	2010-08-12	Genelabs Technologies, Inc.	Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
KR20110118668A (ko)	2009-02-13	2011-10-31	베링거 인겔하임 인터내셔날 게엠베하	１형 당뇨병, ２형 당뇨병, 내당능 장애 또는 고혈당증을 치료하기 위한 ｓｇｌｔ２ 억제제
EP2398791A1 (en)	2009-02-18	2011-12-28	Amgen, Inc	INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
LT3578169T (lt)	2009-02-26	2024-08-26	Glaxo Group Limited	Farmaciniai preparatai, apimantys 4-{(1r)-2-[(6-{2-[(2,6-dichlorbenzil) oksi]etoksi}heksil)amino]-1-hidroksietil}-2-(hidroksimetil)fenolį
US9060927B2 (en) *	2009-03-03	2015-06-23	Biodel Inc.	Insulin formulations for rapid uptake
US11096901B2 (en)	2009-03-06	2021-08-24	Metaqor Llc	Dynamic bio-nanoparticle platforms
US8538707B2 (en)	2009-03-11	2013-09-17	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
CA2756170C (en)	2009-03-23	2019-04-02	The Brigham And Women's Hospital, Inc.	Glycoconjugate vaccines
US7828996B1 (en)	2009-03-27	2010-11-09	Abbott Cardiovascular Systems Inc.	Method for the manufacture of stable, nano-sized particles
WO2010117662A1 (en)	2009-03-30	2010-10-14	Exelixis, Inc.	Modulators of s1p and methods of making and using
WO2010114770A1 (en) *	2009-03-30	2010-10-07	Cerulean Pharma Inc.	Polymer-agent conjugates, particles, compositions, and related methods of use
BRPI1010301A2 (pt) *	2009-04-09	2016-03-15	Alkermes Pharma Ireland Ltd	composição.
US20100268187A1 (en) *	2009-04-17	2010-10-21	Ranbaxy Laboratories Limited	Packaging for sirolimus and composition thereof
SG175315A1 (en)	2009-04-24	2011-11-28	Iceutica Pty Ltd	A novel formulation of indomethacin
KR20120029398A (ko)	2009-04-24	2012-03-26	아이슈티카 피티와이 리미티드	디클로페낙의 신규 제형
US20100291221A1 (en) *	2009-05-15	2010-11-18	Robert Owen Cook	Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US10952965B2 (en) *	2009-05-15	2021-03-23	Baxter International Inc.	Compositions and methods for drug delivery
ES2649112T3 (es)	2009-05-18	2018-01-10	Sigmoid Pharma Limited	Composición que comprende gotas de aceite
EP2253306A1 (en)	2009-05-18	2010-11-24	Royal College of Surgeons in Ireland	Orodispersible dosage forms containing solid drug dispersions
TWI583692B (zh)	2009-05-20	2017-05-21	基利法瑪席特有限責任公司	核苷磷醯胺
WO2010135568A1 (en)	2009-05-22	2010-11-25	Exelixis, Inc.	Benzoxazepines as inhibitors of mtor and their use to treat cancer
WO2010135714A2 (en)	2009-05-22	2010-11-25	The Methodist Hospital Research Institute	Methods for modulating adipocyte expression using microrna compositions
CA2763456C (en)	2009-05-27	2017-10-24	Alkermes Pharma Ireland Limited	Reduction of flake-like aggregation in nanoparticulate active agent compositions
FR2945950A1 (fr)	2009-05-27	2010-12-03	Elan Pharma Int Ltd	Compositions de nanoparticules anticancereuses et procedes pour les preparer
RU2403049C1 (ru) *	2009-06-04	2010-11-10	Государственное образовательное учреждение высшего профессионального образования Московская медицинская академия им. И.М. Сеченова Федерального агентства по здравоохранению и социальному развитию (ГОУВПО ММА им. И.М. Сеченова Росздрава)	Способ получения таблеток эритромицина
TR200904500A2 (tr)	2009-06-10	2009-10-21	Öner Levent	Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
PL2952191T3 (pl)	2009-06-12	2019-02-28	Sunovion Pharmaceuticals Inc.	Apomorfina w postaci do podawania podjęzykowego
RU2509555C2 (ru)	2009-06-12	2014-03-20	Маннкайнд Корпорейшн	Микрочастицы дикетопиперазина с определенными удельными площадями поверхности
SMT202000093T1 (it)	2009-06-16	2020-03-13	Pfizer	Forme di dosaggio di apixaban
US9149024B2 (en)	2009-06-22	2015-10-06	Massachusetts Eye & Ear Infirmary	Islet1 (Isl1) and hearing loss
US8293753B2 (en)	2009-07-02	2012-10-23	Novartis Ag	Substituted 2-carboxamide cycloamino ureas
US20110003000A1 (en) *	2009-07-06	2011-01-06	Femmepharma Holding Company, Inc.	Transvaginal Delivery of Drugs
US9060932B2 (en)	2009-07-09	2015-06-23	Oshadi Drug Administration Ltd.	Matrix carrier compositions, methods and uses
US20130029970A1 (en)	2009-07-10	2013-01-31	Ironwood Pharmaceuticals, Inc	CB Receptor Agonists
EP2283824B1 (en)	2009-07-30	2017-04-19	Special Products Line S.p.A.	Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
AR077692A1 (es)	2009-08-06	2011-09-14	Vitae Pharmaceuticals Inc	Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2770570A1 (en)	2009-08-12	2011-02-17	Sigmoid Pharma Limited	Immunomodulatory compositions comprising a polymer matrix and an oil phase
EP2298296A1 (en)	2009-08-25	2011-03-23	CNRS Centre National De La Recherche Scientifique	Composition and method for treating cognitive impairments in down syndrome subjects
EP2470560B1 (en)	2009-08-28	2015-06-10	Research Development Foundation	Urocortin 2 analogs and uses thereof
US9775819B2 (en) *	2009-09-16	2017-10-03	R.P. Scherer Technologies, Llc	Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US10610489B2 (en)	2009-10-02	2020-04-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
ES2825802T3 (es) *	2009-10-16	2021-05-17	Lifecare Innovations Pvt Ltd	Formulación de anfotericina liposomal que comprende colesterol para tratar infecciones fúngicas
MX338211B (es)	2009-10-22	2016-03-30	Api Genesis Llc	Metodos para hacer y utilizar composiciones que comprenden flavonoides.
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
CN102711749A (zh)	2009-11-05	2012-10-03	莱西肯医药有限公司	用于癌症治疗的色氨酸羟化酶抑制剂
WO2011059931A2 (en) *	2009-11-10	2011-05-19	Celgene Corporation	Nanosuspension of a poorly soluble drug via microfluidization process
GB0921075D0 (en)	2009-12-01	2010-01-13	Glaxo Group Ltd	Novel combination of the therapeutic agents
HUE038821T2 (hu)	2009-12-03	2018-11-28	Novartis Ag	Karboxivinil polimert tartalmazó nanorészecske szuszpenziók
US8975251B2 (en) *	2009-12-09	2015-03-10	Bar-Ilan University	Methods of improving cognitive functions
EP2509960A1 (en)	2009-12-11	2012-10-17	Exelixis, Inc.	Tgr5 agonists
EP2512600A2 (en)	2009-12-18	2012-10-24	Amgen Inc.	Wise binding agents and epitopes
CN102770125B (zh)	2009-12-22	2015-02-11	利奥制药有限公司	钙泊三醇一水化合物纳米晶体
KR20120098908A (ko)	2009-12-23	2012-09-05	아이언우드 파마슈티컬스, 인코포레이티드	Ｃｒｔｈ２ 조절제
UA110103C2 (uk)	2010-01-27	2015-11-25	Ґлаксосмітклайн Байолоджікалз С.А.	Модифікований туберкульозний антиген
US9028873B2 (en) *	2010-02-08	2015-05-12	Southwest Research Institute	Nanoparticles for drug delivery to the central nervous system
WO2011100324A1 (en)	2010-02-09	2011-08-18	Ironwood Pharmaceuticals Inc.	Cannabinoid receptor agonists
WO2011100359A1 (en)	2010-02-09	2011-08-18	Ironwood Pharmaceuticals, Inc.	Cannabinoid agonists
US8901137B2 (en)	2010-02-09	2014-12-02	Exelixis, Inc.	Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
CN102753168A (zh)	2010-02-10	2012-10-24	莱西肯医药有限公司	用于治疗转移性骨病的色氨酸羟化酶抑制剂
EP2536689A1 (en)	2010-02-17	2012-12-26	Amgen Inc.	Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
RU2012139182A (ru)	2010-02-22	2014-03-27	Ф. Хоффманн-Ля Рош Аг	ПИРИДО[3,2-d]ПИРИМИДИНЫ - ИНГИБИТОРЫ PI3К ДЕЛЬТА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2013520488A (ja) *	2010-02-24	2013-06-06	ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド	ペルフェナジン−ｇａｂａのトリメシラート塩の結晶性形態物及びその製法方法
WO2011111794A1 (ja) *	2010-03-11	2011-09-15	浜松ホトニクス株式会社	微粒子分散液製造方法および微粒子分散液製造装置
KR101834940B1 (ko)	2010-03-22	2018-03-06	(주)바이오시네틱스	나노입자 제조방법
RS54368B1 (sr)	2010-03-31	2016-04-28	Gilead Pharmasset Llc	Kristalni (s)-izopropil 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-diokso-3,4-dihidropirimidin-1-(2h)-il)-4-fluoro-3-hidroksi-4-metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
UY33312A (es)	2010-03-31	2011-10-31	Pharmasset Inc	Fosforamidato de nucleosido de purina
US8563530B2 (en)	2010-03-31	2013-10-22	Gilead Pharmassel LLC	Purine nucleoside phosphoramidate
DE102010003711B4 (de)	2010-04-08	2015-04-09	Jesalis Pharma Gmbh	Verfahren zur Herstellung kristalliner Wirkstoffpartikel
US20110269735A1 (en)	2010-04-19	2011-11-03	Celera Corporation	Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
ES2711256T3 (es)	2010-04-23	2019-04-30	Univ Florida	Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
US9101541B2 (en)	2010-04-28	2015-08-11	Cadila Healthcare Limited	Stable solid pharmaceutical matrix compositions of sirolimus
US20130116333A1 (en) *	2010-05-05	2013-05-09	Ratiopharm Gmbh	Solid tapentadol in non-crystalline form
US8362007B1 (en)	2010-05-11	2013-01-29	Demerx, Inc.	Substituted noribogaine
US9394294B2 (en)	2010-05-11	2016-07-19	Demerx, Inc.	Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en)	2010-05-11	2014-07-01	Demerx, Inc.	Methods and compositions for preparing and purifying noribogaine
WO2011143495A1 (en)	2010-05-13	2011-11-17	Amgen Inc.	Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
JP2013526524A (ja)	2010-05-13	2013-06-24	アムジエン・インコーポレーテツド	Ｐｄｅ１０阻害剤としてのアリールおよびヘテロアリール窒素ヘテロ環式化合物
AU2011253057B2 (en)	2010-05-13	2014-11-20	Amgen Inc.	Nitrogen heterocyclic compounds useful as PDE10 inhibitors
EP2569306A1 (en)	2010-05-13	2013-03-20	Amgen Inc.	Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
SMT202000095T1 (it)	2010-05-14	2020-03-13	Amgen Inc	Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
US9012511B2 (en)	2010-05-19	2015-04-21	Alkermes Pharma Ireland Limited	Nanoparticulate cinacalcet compositions
HUP1000325A2 (en)	2010-06-18	2012-01-30	Druggability Technologies Ip Holdco Jersey Ltd	Nanostructured aprepitant compositions and process for their preparation
MX359281B (es)	2010-06-21	2018-09-21	Mannkind Corp	Sistema y metodos para suministrar un farmaco en polvo seco.
US8741891B1 (en)	2010-06-22	2014-06-03	Demerx, Inc.	N-substituted noribogaine prodrugs
US8637648B1 (en)	2010-06-22	2014-01-28	Demerx, Inc.	Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8802832B2 (en)	2010-06-22	2014-08-12	Demerx, Inc.	Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en)	2010-06-22	2017-03-07	Demerx, Inc.	N-substituted noribogaine prodrugs
EP3263111A1 (en)	2010-06-30	2018-01-03	Victoria Link Ltd	Methods and compositions for treatment of multiple sclerosis
AR084469A1 (es)	2010-07-09	2013-05-22	Exelixis Inc	Combinaciones de inhibidores de quinasas para el tratamiento del cancer
US20130216552A1 (en)	2010-07-12	2013-08-22	Ironwood Pharmaceuticals, Inc.	Crth2 modulators
WO2012009134A1 (en)	2010-07-12	2012-01-19	Ironwood Pharmaceuticals, Inc.	Crth2 modulators
US9358237B2 (en)	2010-07-23	2016-06-07	Demerx, Inc.	Noribogaine compositions
AU2011291506B2 (en)	2010-08-19	2016-07-28	Buck Institute For Age Research	Methods of treating mild cognitive impairment (mci) and related disorders
ES2612503T3 (es)	2010-09-14	2017-05-17	Exelixis, Inc.	Compuestos 9H-purina como inhibidores de PI3K-delta y métodos para su preparación
AU2011302196B2 (en)	2010-09-14	2016-04-28	Exelixis, Inc.	Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012037132A1 (en)	2010-09-14	2012-03-22	Exelixis, Inc.	Phtalazine derivatives as jak1 inhibitors
WO2012038963A1 (en)	2010-09-22	2012-03-29	Ramot At Tel-Aviv University Ltd.	An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
CN103221049B (zh)	2010-09-23	2015-11-25	诺弗米克斯有限公司	阿瑞匹坦l-脯氨酸组合物和共晶
WO2012044577A1 (en)	2010-09-27	2012-04-05	Exelixis, Inc.	Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
PL2621481T5 (pl)	2010-09-27	2023-03-13	Exelixis, Inc.	Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości
JP2013540759A (ja)	2010-09-27	2013-11-07	エクセリクシス，インク．	去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
WO2012051426A2 (en) *	2010-10-15	2012-04-19	Glaxo Group Limited	Aggregate nanoparticulate medicament formulations, manufacture and use thereof
WO2012061337A1 (en)	2010-11-02	2012-05-10	Exelixis, Inc.	Fgfr2 modulators
US20120108651A1 (en)	2010-11-02	2012-05-03	Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL)	Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
RU2632445C2 (ru) *	2010-11-02	2017-10-04	Боард Оф Реджентс Оф Де Юниверсити Оф Небраска	Композиции и способы доставки терапевтических средств
WO2012065057A2 (en)	2010-11-12	2012-05-18	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2012065019A2 (en)	2010-11-12	2012-05-18	Exelixis, Inc.	Pyridopyrimidinone inhibitors of p13k alpha
WO2012068106A2 (en)	2010-11-15	2012-05-24	Exelixis, Inc.	Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
US20140080810A1 (en)	2010-11-15	2014-03-20	Exelixis, Inc.	Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
WO2012071509A2 (en)	2010-11-24	2012-05-31	Exelixis, Inc.	Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture
GB201020032D0 (en)	2010-11-25	2011-01-12	Sigmoid Pharma Ltd	Composition
EP3042910B1 (en)	2010-11-30	2019-01-09	Gilead Pharmasset LLC	2'-spiro-nucleosides for use in the therapy of hepatitis c
US20180153904A1 (en)	2010-11-30	2018-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9034858B2 (en)	2010-11-30	2015-05-19	Lipocine Inc.	High-strength testosterone undecanoate compositions
US9358241B2 (en)	2010-11-30	2016-06-07	Lipocine Inc.	High-strength testosterone undecanoate compositions
EP2649065A1 (en)	2010-12-09	2013-10-16	Amgen Inc.	Bicyclic compounds as pim inhibitors
US20120148675A1 (en)	2010-12-10	2012-06-14	Basawaraj Chickmath	Testosterone undecanoate compositions
DK2651357T3 (da)	2010-12-16	2020-06-02	Sunovion Pharmaceuticals Inc	Sublinguale film
US9351989B2 (en)	2010-12-29	2016-05-31	Inhibitex, Inc.	Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
WO2012094451A1 (en)	2011-01-06	2012-07-12	Beta Pharma Canada Inc.	Novel ureas for the treatment and prevention of cancer
EP2481740B1 (en)	2011-01-26	2015-11-04	DemeRx, Inc.	Methods and compositions for preparing noribogaine from voacangine
MX2013010011A (es)	2011-03-01	2014-10-24	Amgen Inc	Agentes de unión biespecífica.
US9321756B2 (en)	2011-03-22	2016-04-26	Amgen Inc.	Azole compounds as PIM inhibitors
SG10201701634PA (en)	2011-03-25	2017-04-27	Amgen Inc	Anti - sclerostin antibody crystals and formulations thereof
US8925726B2 (en)	2011-04-01	2015-01-06	Mannkind Corporation	Blister package for pharmaceutical cartridges
ES2823805T3 (es)	2011-04-15	2021-05-10	Janssen Pharmaceutica Nv	Nanosuspensiones de fármacos secadas por congelamiento
US8883497B2 (en)	2011-04-28	2014-11-11	University Of Southern California	Human myeloid derived suppressor cell cancer markers
CN103635183A (zh)	2011-04-29	2014-03-12	埃克塞利希斯股份有限公司	使用pi3k/mtor的吡啶并嘧啶抑制剂来治疗淋巴瘤的方法
JP2014516941A (ja)	2011-04-29	2014-07-17	アムジェンインコーポレイテッド	Ｐｉｍ阻害剤としての二環式ピリダジン化合物
US9221760B2 (en)	2011-05-09	2015-12-29	Van Andel Research Institute	Autophagy inhibitors
US8709034B2 (en)	2011-05-13	2014-04-29	Broncus Medical Inc.	Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
JP2014521381A (ja)	2011-05-13	2014-08-28	ブロンカステクノロジーズ，インコーポレイテッド	組織の切除のための方法およびデバイス
WO2012158810A1 (en)	2011-05-17	2012-11-22	Principia Biopharma Inc.	Tyrosine kinase inhibitors
US8962831B2 (en)	2011-05-17	2015-02-24	Principia Biopharma Inc.	Tyrosine kinase inhibitors
US9376438B2 (en)	2011-05-17	2016-06-28	Principia Biopharma, Inc.	Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
CA2836417A1 (en)	2011-05-17	2012-11-22	Principia Biopharma Inc.	Azaindole derivatives as tyrosine kinase inhibitors
EP4085899A1 (en)	2011-06-14	2022-11-09	Neurelis, Inc.	Administration of benzodiazepine
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
MX2013013627A (es)	2011-06-21	2014-04-25	Oncofactor Corp	Composiciones y metodos para la terapia y diagnostico de cancer.
JP5978296B2 (ja)	2011-06-28	2016-08-24	フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド	抗アレルギ性ベンゾシクロヘプタチオフェン誘導体
WO2013012649A1 (en)	2011-07-15	2013-01-24	Glaxosmithkline Llc	Azaindole compounds and methods for treating hiv
EP2734204A4 (en)	2011-07-22	2015-03-18	Chemocentryx Inc	POLYMORPHIC FORMS OF 4-TERT-BUTYL-N- [4-CHLORO-2- (1-OXY-PYRIDINE-4-CARBONYL) -PHENYL] -BENZENE-SULFONAMIDE SODIUM SALT
MX350269B (es)	2011-07-22	2017-08-31	Chemocentryx Inc	Una forma cristalina de la sal de sodio de 4-ter-butil-n-[4-cloro- 2-(1-oxi-piridina-4-carbonil)-fenil]-bencensulfonamida.
MX355816B (es)	2011-08-04	2018-05-02	Amgen Inc	Metodo para tratar los defectos de espacio oseo.
US9617274B1 (en)	2011-08-26	2017-04-11	Demerx, Inc.	Synthetic noribogaine
PH12014500382A1 (en)	2011-09-01	2021-07-12	Glaxo Group Ltd	Novel crystal form
AU2012308414A1 (en)	2011-09-14	2014-05-01	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
KR101794032B1 (ko)	2011-09-21	2017-11-07	(주)바이오시네틱스	나노입자 제조방법
WO2013043553A1 (en)	2011-09-22	2013-03-28	Glaxosmithkline Llc	Pyrrolopyridinone compounds and methods for treating hiv
AU2012312364B2 (en)	2011-09-22	2017-11-09	Exelixis, Inc.	Method for treating osteoporosis
AU2012315545B2 (en)	2011-09-29	2017-03-09	Plx Opco Inc.	pH dependent carriers for targeted release of pharmaceuticals along the gastrointestinal tract, compositions therefrom, and making and using same
WO2013056067A1 (en)	2011-10-13	2013-04-18	Exelixis, Inc.	Compounds for use in the treatment of basal cell carcinoma
TWI580442B (zh) *	2011-10-19	2017-05-01	傑特大學	醫藥毫微懸浮物
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
JP6013498B2 (ja)	2011-11-01	2016-10-25	エクセリクシス，インク．	リンパ増殖性悪性疾患の治療のためのホスファチジルイノシトール３−キナーゼ阻害剤としてのｎ−（３−｛［（３−｛［２−クロロ−５−（メトキシ）フェニル］アミノ｝キノキサリン−２−イル）アミノ］スルホニル｝フェニル）−２−メチルアラニンアミド
WO2013067306A1 (en)	2011-11-02	2013-05-10	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
IN2014CN04067A (zh)	2011-11-08	2015-10-23	Exelixis Inc
KR20140094597A (ko)	2011-11-08	2014-07-30	엑셀리시스, 인코포레이티드	암 치료를 정량하는 방법
AU2012335073B2 (en)	2011-11-11	2017-08-17	Fred Hutchinson Cancer Center	Cyclin A1-targeted T-cell immunotherapy for cancer
WO2013074988A1 (en)	2011-11-17	2013-05-23	The Regents Of The University Of Colorado, A Body Corporate	Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
WO2013078235A1 (en)	2011-11-23	2013-05-30	Broncus Medical Inc	Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
US9532993B2 (en)	2011-11-25	2017-01-03	Nuformix Limited	Aprepitant L-proline solvates—compositions and cocrystals
EP2788003A4 (en)	2011-12-09	2015-05-27	Demerx Inc	PHOSPHATESTER OF NORIBOGAIN
JO3387B1 (ar)	2011-12-16	2019-03-13	Glaxosmithkline Llc	مشتقات بيتولين
CN107126560A (zh)	2011-12-28	2017-09-05	安进公司	通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法
CA2858820C (en)	2012-01-25	2021-08-17	Demerx, Inc.	Synthetic voacangine
US9150584B2 (en)	2012-01-25	2015-10-06	Demerx, Inc.	Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
CA2863083C (en)	2012-01-26	2023-09-19	Longhorn Vaccines And Diagnostics, Llc	Composite antigenic sequences and vaccines
TW201348226A (zh)	2012-02-28	2013-12-01	Amgen Inc	作為ｐｉｍ抑制劑之醯胺
TW201348231A (zh)	2012-02-29	2013-12-01	Amgen Inc	雜雙環化合物
MX387450B (es)	2012-03-19	2025-03-04	Cidara Therapeutics Inc	Regimenes de dosificacion para compuestos de la clase de las equinocandinas.
KR20140139563A (ko)	2012-03-22	2014-12-05	나노테라퓨틱스, 인코포레이티드	캡슐화된 디에틸렌트리아민펜타아세테이트 입자들의 경구 전달을 위한 조성물 및 방법
KR101956586B1 (ko) *	2012-03-27	2019-03-11	일양약품주식회사	약제학적 조성물 및 이의 제조방법
WO2013148978A1 (en)	2012-03-30	2013-10-03	Lexicon Pharmaceuticals, Inc.	Methods and compositions for the treatment of necrotizing enterocolitis
WO2013155422A1 (en)	2012-04-12	2013-10-17	Ironwood Pharmaceuticals, Inc.	Methods of treating alopecia and acne
US9452107B2 (en)	2012-04-16	2016-09-27	New Jersey Institute Of Technology	Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
EP2844254A1 (en)	2012-05-02	2015-03-11	Exelixis, Inc.	A dual met - vegf modulator for treating osteolytic bone metastases
EP3808339B1 (en)	2012-05-03	2025-11-12	Alcon Inc.	Pharmaceutical nanoparticles showing improved mucosal transport
WO2013166385A1 (en)	2012-05-03	2013-11-07	Kala Pharmaceuticals, Inc.	Pharmaceutical nanoparticles showing improved mucosal transport
US11596599B2 (en)	2012-05-03	2023-03-07	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
US9827191B2 (en)	2012-05-03	2017-11-28	The Johns Hopkins University	Compositions and methods for ophthalmic and/or other applications
IN2014MN02002A (zh)	2012-05-11	2015-08-07	Activus Pharma Co Ltd
CA2872021C (en)	2012-05-17	2022-08-16	Transtech Pharma, Llc	Glucokinase activator compositions for the treatment of diabetes
CA2875986C (en)	2012-06-04	2020-06-09	Pharmacyclics, Inc.	Crystalline forms of a bruton's tyrosine kinase inhibitor
UY34858A (es)	2012-06-14	2013-11-29	Amgen Inc	Compuestos de azetidina y piperidina útiles como inhibidores de pde10
CA2914782C (en)	2012-06-21	2021-05-25	Phosphorex, Inc.	Nanoparticles of indirubin, derivatives thereof and methods of making and using same
EP2869844B2 (en)	2012-07-05	2023-06-21	UCB Pharma S.A.	Treatment for bone diseases
GB201212010D0 (en)	2012-07-05	2012-08-22	Sigmoid Pharma Ltd	Formulations
MX354163B (es)	2012-07-12	2018-02-15	Mannkind Corp	Sistemas y métodos de suministro de fármaco en polvo seco.
ES2647437T3 (es)	2012-07-12	2017-12-21	Viiv Healthcare Uk Limited	Compuestos y procedimientos para tratar el VIH
JOP20130213B1 (ar)	2012-07-17	2021-08-17	Takeda Pharmaceuticals Co	معارضات لمستقبلht3-5
WO2014022752A1 (en)	2012-08-03	2014-02-06	Amgen Inc.	Macrocycles as pim inhibitors
US9487526B2 (en)	2012-08-13	2016-11-08	Takeda Pharmaceutical Company Limited	Quinoxaline derivatives as GPR6 modulators
US10945984B2 (en)	2012-08-22	2021-03-16	Arbor Pharmaceuticals, Llc	Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
AU2013305684B2 (en)	2012-08-22	2016-11-24	Xenoport, Inc.	Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
US9605276B2 (en)	2012-08-24	2017-03-28	Etubics Corporation	Replication defective adenovirus vector in vaccination
US9750705B2 (en)	2012-08-31	2017-09-05	The Regents Of The University Of California	Agents useful for treating obesity, diabetes and related disorders
EP2890691B1 (en)	2012-08-31	2018-04-25	Principia Biopharma Inc.	Benzimidazole derivatives as itk inhibitors
JP6203848B2 (ja)	2012-09-10	2017-09-27	プリンシピアバイオファーマインコーポレイテッド	キナーゼ阻害剤としてのピラゾロピリミジン化合物
EP2911690A1 (en)	2012-10-26	2015-09-02	MannKind Corporation	Inhalable influenza vaccine compositions and methods
AU2013348116A1 (en)	2012-11-20	2015-06-11	Principia Biopharma Inc.	Azaindole derivatives as JAK3 inhibitors
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
EP2925764B1 (en)	2012-11-30	2023-03-01	Sanford-Burnham Medical Research Institute	Inhibitor of apoptosis protein (iap) antagonists
WO2014091318A1 (en)	2012-12-11	2014-06-19	Lupin Atlantis Holdings, S.A.	Reduced dose pharmaceutical compositions of fenofibrate
WO2014100021A1 (en)	2012-12-17	2014-06-26	Exelixis, Inc.	Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
US9045481B2 (en)	2012-12-20	2015-06-02	Demerx, Inc.	Substituted noribogaine
CA2896133A1 (en)	2012-12-20	2014-06-26	Demerx, Inc.	Substituted noribogaine
US8940728B2 (en)	2012-12-20	2015-01-27	Demerx, Inc.	Substituted noribogaine
JP2016508504A (ja)	2013-02-01	2016-03-22	サンタマリアバイオセラピューティクスインコーポレイテッド	対象に対する抗アクチビン−ａ化合物の投与
CN105121023B (zh) *	2013-02-28	2017-08-25	太阳化学公司	用于在液体分散液中制造研磨的固体的装置和连续方法
CA2903433A1 (en) *	2013-03-04	2014-09-12	Vtv Therapeutics Llc	Stable glucokinase activator compositions
WO2014160177A2 (en)	2013-03-13	2014-10-02	Exelixis, Inc.	Quinazoline inhibitors of pi3k
EP2968376B1 (en)	2013-03-15	2019-06-05	GlaxoSmithKline Biologicals S.A.	Composition containing buffered aminoalkyl glucosaminide phosphate derivatives and its use for enhancing an immune response
US9732068B1 (en)	2013-03-15	2017-08-15	GenSyn Technologies, Inc.	System for crystalizing chemical compounds and methodologies for utilizing the same
SG10201708090TA (en)	2013-03-15	2017-11-29	Mannkind Corp	Microcrystalline diketopiperazine compositions and methods
US10179118B2 (en)	2013-03-24	2019-01-15	Arbor Pharmaceuticals, Llc	Pharmaceutical compositions of dimethyl fumarate
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HUE041709T2 (hu)	2013-04-05	2019-05-28	Boehringer Ingelheim Int	Az empagliflozin terápiás alkalmazásai
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
AU2014255727B2 (en)	2013-04-18	2019-07-25	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9630963B2 (en)	2013-05-09	2017-04-25	Principia Biopharma, Inc.	Quinolone derivatives as fibroblast growth factor inhibitors
US9302977B2 (en)	2013-06-07	2016-04-05	Xenoport, Inc.	Method of making monomethyl fumarate
EP3010489A1 (en)	2013-06-20	2016-04-27	Glenmark Pharmaceuticals S.A.	Nanoparticulate formulation comprising a trpa1 antagonist
WO2014205392A1 (en)	2013-06-21	2014-12-24	Xenoport, Inc.	Cocrystals of dimethyl fumarate
KR102321339B1 (ko)	2013-07-18	2021-11-02	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
CA2920488C (en)	2013-08-05	2022-04-26	Mannkind Corporation	Insufflation apparatus and methods
EP3041467A1 (en)	2013-09-06	2016-07-13	XenoPort, Inc.	Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en)	2013-09-18	2015-03-26	Xenoport, Inc.	Nanoparticle compositions of dimethyl fumarate
GB201319791D0 (en)	2013-11-08	2013-12-25	Sigmoid Pharma Ltd	Formulations
WO2015071841A1 (en)	2013-11-12	2015-05-21	Druggability Technologies Holdings Limited	Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP2878311A1 (en)	2013-11-27	2015-06-03	Freund Pharmatec Ltd.	Solubility Enhancement for Hydrophobic Drugs
JP6510539B2 (ja)	2014-01-09	2019-05-08	ザジェイ．デヴィッドグラッドストーンインスティテューツ，アテスタメンタリートラストエスタブリッシュドアンダーザウィルオブジェイ．デヴィッドグラッドストーン	置換ベンゾオキサジン及び関連化合物
WO2015108945A2 (en)	2014-01-14	2015-07-23	Board Of Regents Of The University Of Nebraska	Compositions and methods for the delivery of therapeutics
US10898581B2 (en)	2014-01-16	2021-01-26	The Brigham And Women's Hospital, Inc.	Targeted delivery of immunoregulatory drugs
KR20160117614A (ko)	2014-02-21	2016-10-10	프린시피아 바이오파마, 인코퍼레이티드	Btk 억제제의 염 및 고체 형태
EP3114124A1 (en)	2014-03-03	2017-01-11	Principia Biopharma, Inc.	BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
WO2015134608A1 (en)	2014-03-05	2015-09-11	Nanotherapeutics, Inc.	Compositions and methods for oral delivery of encapsulated 3-aminopyridine-2-carboxaldehyde particles
US9999672B2 (en)	2014-03-24	2018-06-19	Xenoport, Inc.	Pharmaceutical compositions of fumaric acid esters
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
BR112016024672A2 (pt)	2014-04-25	2021-02-02	Exelixis, Inc	método para o tratamento de adenocarcinoma de pulmão
KR20170003673A (ko)	2014-05-12	2017-01-09	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	감염성 질환을 치료하기 위한 다니릭신을 포함하는 약제 조성물
CA2950911C (en)	2014-06-04	2023-10-10	Sanford-Burnham Medical Research Institute	Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
US9526734B2 (en)	2014-06-09	2016-12-27	Iceutica Pty Ltd.	Formulation of meloxicam
WO2015195673A2 (en)	2014-06-18	2015-12-23	Demerx, Inc.	Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US10654843B2 (en)	2014-06-20	2020-05-19	Principia Biopharma Inc.	LMP7 inhibitors
CA2952567A1 (en)	2014-06-25	2015-12-30	Glaxosmithkline Intellectual Property Development Limited	Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
WO2016016861A1 (en) *	2014-08-01	2016-02-04	Glenmark Pharmaceuticals S.A.	Nanoparticulate formulation comprising a mpges-1 inhibitor
CN106794251B (zh) *	2014-08-18	2020-12-29	阿尔科姆斯制药爱尔兰有限公司	阿立哌唑前体药物组合物
US10016415B2 (en)	2014-08-18	2018-07-10	Alkermes Pharma Ireland Limited	Aripiprazole prodrug compositions
WO2016033556A1 (en)	2014-08-28	2016-03-03	Lipocine Inc.	BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en)	2014-08-28	2017-08-31	Lipocine Inc.	(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
KR20170054429A (ko)	2014-09-03	2017-05-17	제네세규스 인코포레이티드	치료용 나노입자 및 관련 조성물, 방법, 및 시스템
KR20170047396A (ko)	2014-09-08	2017-05-04	글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드	2-(4-(4-에톡시-6-옥소-1,6-디히드로피리딘-3-일)-2-플루오로페닐)-n-(5-(1,1,1-트리플루오로-2-메틸프로판-2-일)이속사졸-3-일)아세트아미드의 결정질 형태
MA40771B1 (fr)	2014-09-29	2021-09-30	Takeda Pharmaceuticals Co	Forme cristalline de 1-(1-méthyl-1h-pyrazol -4-yl)-n- ((1r,5s,7s) -9-méthyl-3-oxa-9-azabicyclo[3.3.1]nonan-7-yl)-1h-indole-3-carboxamide
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
EP3203995A4 (en)	2014-10-09	2019-05-15	Board of Regents of the University of Nebraska	COMPOSITIONS AND METHODS OF DELIVERING THERAPY AGENTS
SMT202100137T1 (it)	2014-11-07	2021-05-07	Sublimity Therapeutics Ltd	Composizioni comprendenti la ciclosporina
ES2890662T3 (es) *	2014-11-25	2022-01-21	Curadigm Sas	Composiciones farmacéuticas, preparación y usos de las mismas
MA41142A (fr)	2014-12-12	2017-10-17	Amgen Inc	Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
ES2795833T3 (es)	2015-01-09	2020-11-24	Etubics Corp	Composiciones para la vacunación contra el virus del Ebola
CN104587457B (zh) *	2015-01-13	2017-03-22	广东海大畜牧兽医研究院有限公司	一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
US10166197B2 (en)	2015-02-13	2019-01-01	St. John's University	Sugar ester nanoparticle stabilizers
MX369634B (es)	2015-02-20	2019-11-14	Cytec Ind Inc	Composiciones de dialquil sulfosuccinato, metodos para hacerlas y metodos de uso.
IL315294A (en)	2015-03-03	2024-10-01	Pharmacyclics Llc	Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
EP3274053A4 (en)	2015-03-23	2018-12-05	The Brigham and Women's Hospital, Inc.	Tolerogenic nanoparticles for treating diabetes mellitus
EP3285771B1 (en)	2015-04-21	2025-02-12	Sunovion Pharmaceuticals Inc.	Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US9976136B2 (en)	2015-05-14	2018-05-22	Longhorn Vaccines And Diagnostics, Llc	Rapid methods for the extraction of nucleic acids from biological samples
US10538517B2 (en)	2015-05-22	2020-01-21	Principia Biopharma, Inc.	Quinolone derivatives as FGFR inhibitors
LT3303334T (lt)	2015-06-03	2021-07-12	Principia Biopharma Inc.	Tirozinkinazės inhibitoriai
US20160361322A1 (en)	2015-06-15	2016-12-15	Lipocine Inc.	Composition and method for oral delivery of androgen prodrugs
EP3313839A1 (en)	2015-06-24	2018-05-02	Principia Biopharma Inc.	Tyrosine kinase inhibitors
WO2017004610A1 (en)	2015-07-02	2017-01-05	Exelixis, Inc.	Tercyclic s1p3-sparing, s1p1 receptor agonists
WO2017002078A1 (en)	2015-07-02	2017-01-05	Glaxosmithkline Intellectual Property Development Limited	Inhibitors of indoleamine 2,3-dioxygenase
WO2017004609A1 (en)	2015-07-02	2017-01-05	Exelixis, Inc.	Thiadiazole modulators of s1p and methods of making and using
WO2017004608A1 (en)	2015-07-02	2017-01-05	Exelixis, Inc.	Oxadiazole modulators of s1p methods of making and using
KR20180028535A (ko)	2015-07-28	2018-03-16	글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드	Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
JP2018521093A (ja)	2015-07-28	2018-08-02	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙ（Ｎｏ．２）Ｌｉｍｉｔｅｄ	Ｈｉｖ感染を予防または治療するためのベツイン誘導体
RU2018112830A (ru)	2015-09-24	2019-10-24	ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед	Модуляторы индоламин-2,3-диоксигеназы
AU2016327167B2 (en)	2015-09-24	2018-11-08	Glaxosmithkline Intellectual Property (No.2) Limited	Modulators of indoleamine 2,3-dioxygenase
RU2018112958A (ru)	2015-09-24	2019-10-28	ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед	Соединения с ингибирующей созревание ВИЧ активностью
CN108135838A (zh)	2015-10-16	2018-06-08	马瑞纳斯制药公司	包含纳米粒的可注射神经类固醇制剂
WO2017130156A1 (en)	2016-01-27	2017-08-03	Glaxosmithkline Intellectual Property (No.2) Limited	Ingenol analogs, pharmaceutical compositions and methods of use thereof
WO2017143017A1 (en)	2016-02-17	2017-08-24	Alkermes Pharma Ireland Limited	Compositions of multiple aripiprazole prodrugs
EP3416963B1 (en)	2016-02-17	2021-07-28	Global Blood Therapeutics, Inc.	Histone methyltransferase inhibitors
EP3426674A4 (en)	2016-03-09	2019-08-14	Blade Therapeutics, Inc.	CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
GB201604124D0 (en)	2016-03-10	2016-04-27	Ucb Biopharma Sprl	Pharmaceutical formulation
US10682340B2 (en)	2016-06-30	2020-06-16	Durect Corporation	Depot formulations
GEP20207204B (en)	2016-06-30	2020-12-25	Santen Pharmaceutical Co Ltd	Depot formulations
TW201811376A (zh)	2016-07-01	2018-04-01	英商葛蘭素史密斯克藍智慧財產權有限公司	抗體-藥物結合物及使用其之治療方法
EP3481835A4 (en)	2016-07-05	2020-02-26	Blade Therapeutics, Inc.	CALPAIN MODULATORS AND THERAPEUTIC USE THEREOF
EP4233861A3 (en)	2016-08-11	2023-10-11	Ovid Therapeutics, Inc.	Compositions for treatment of essential tremor
EP4190328A1 (en)	2016-08-19	2023-06-07	Orasis Pharmaceuticals Ltd.	Ophthalmic pharmaceutical compositions and uses relating thereto
US10391105B2 (en)	2016-09-09	2019-08-27	Marinus Pharmaceuticals Inc.	Methods of treating certain depressive disorders and delirium tremens
WO2018049324A1 (en)	2016-09-12	2018-03-15	Numerate, Inc.	Monocyclic compounds useful as gpr120 modulators
WO2018052053A1 (ja)	2016-09-13	2018-03-22	協和発酵キリン株式会社	医薬組成物
US10934261B2 (en)	2016-09-28	2021-03-02	Blade Therapeutics, Inc.	Calpain modulators and therapeutic uses thereof
US11160743B2 (en)	2016-10-11	2021-11-02	Dsm Ip Assets B.V.	Preparation of nano-sized UV absorbers
CN109922813A (zh)	2016-11-10	2019-06-21	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
US20180147215A1 (en)	2016-11-28	2018-05-31	Lipocine Inc.	Oral testosterone undecanoate therapy
EP4592046A3 (en)	2016-12-16	2025-09-24	Koppers Performance Chemicals, Inc.	Wood preservative and method for producing same
WO2018119208A1 (en)	2016-12-22	2018-06-28	Global Blood Therapeutics, Inc.	Histone methyltransferase inhibitors
PL3571208T3 (pl)	2017-01-18	2021-09-20	Principia Biopharma Inc.	Inhibitory immunoproteasomu
MX2019012176A (es)	2017-04-10	2020-02-19	Sierra Oncology Inc	Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
WO2018191418A1 (en)	2017-04-11	2018-10-18	Saje Pharma, Llc	Carbazole compounds and methods of use thereof
AU2018255063A1 (en)	2017-04-21	2018-11-22	Bio-Synectics Inc.	Method for preparing active material nanoparticles using lipid as lubricant for milling
ES2949402T3 (es)	2017-06-09	2023-09-28	Global Blood Therapeutics Inc	Compuestos de azaindol como inhibidores de la histona metiltransferasa
KR20240108542A (ko)	2017-07-14	2024-07-09	얀센 파마슈티카 엔브이	장기 작용 제형
WO2019036384A1 (en)	2017-08-15	2019-02-21	Global Blood Therapeutics, Inc.	TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
WO2019036377A1 (en)	2017-08-15	2019-02-21	Global Blood Therapeutics, Inc.	TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
WO2019087016A1 (en)	2017-10-30	2019-05-09	Glaxosmithkline Intellectual Property Development Limited	Compounds useful in hiv therapy
EP3710458B1 (en)	2017-11-16	2026-03-25	Principia Biopharma Inc.	Immunoproteasome inhibitors
CN111491939B (zh)	2017-11-16	2023-12-26	普林斯匹亚生物制药公司	免疫蛋白酶体抑制剂
WO2019140365A1 (en)	2018-01-12	2019-07-18	Board Of Regents Of The University Of Nebraska	Antiviral prodrugs and formulations thereof
DE102018103528A1 (de)	2018-02-16	2019-08-22	Friedrich-Alexander-Universität Erlangen-Nürnberg	Suspension nanoskaliger, organischer Partikel und Verfahren zu ihrer Herstellung
WO2019169029A1 (en)	2018-02-28	2019-09-06	Bioxiness Pharmaceuticals, Inc.	Target specific chemotherapeutic agents
WO2019169017A1 (en)	2018-02-28	2019-09-06	Bioxiness Pharmaceuticals, Inc.	Chemotherapeutic agents
WO2019171285A1 (en)	2018-03-07	2019-09-12	Glaxosmithkline Intellectual Property (No.2) Limited	Compounds useful in hiv therapy
EP3762104A2 (en) *	2018-03-07	2021-01-13	ST IP Holding AG	Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
BR112020020080A2 (pt)	2018-03-30	2021-01-05	Amgen Inc	Variantes de anticorpos c-terminais
CA3132832A1 (en)	2018-04-09	2019-10-17	Howard E. Gendelman	Antiviral prodrugs and formulations thereof
AU2019287313B2 (en)	2018-06-11	2024-08-01	Otsuka Pharmaceutical Co., Ltd.	Delamanid-containing composition
CN112040945A (zh)	2018-06-12	2020-12-04	Vtv治疗有限责任公司	葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
JP2021531348A (ja)	2018-07-20	2021-11-18	リポシン，インク．	肝臓病
CN112789085A (zh)	2018-08-09	2021-05-11	葛兰素史克知识产权第二有限公司	可用于hiv疗法的化合物
EP3840754A4 (en)	2018-08-23	2022-09-14	Sunovion Pharmaceuticals Inc.	ACID ADDITIONAL SALTS OF APOMORPHINE, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF USE THEREOF
WO2020044257A1 (en)	2018-08-30	2020-03-05	Glaxosmithkline Intellectual Property (No.2) Limited	Compounds useful in hiv therapy
CA3113621A1 (en)	2018-09-24	2020-04-02	Sierra Oncology, Inc.	Methods of treatment of cancer comprising cdc7 inhibitors
WO2020121006A2 (en)	2018-10-19	2020-06-18	Innostudio Inc.	Method and apparatus to produce nanoparticles in an ostwald ripening flow device with tubes of variable path length
CN113613724B (zh)	2018-11-30	2024-11-08	葛兰素史克知识产权开发有限公司	可用于hiv疗法的化合物
WO2020118142A1 (en)	2018-12-07	2020-06-11	Marinus Pharmaceuticals, Inc.	Ganaxolone for use in prophylaxis and treatment of pospartum depression
LT3924349T (lt)	2019-01-22	2025-10-10		Aminorūgščių dariniai uždegiminių ligų gydymui
CA3130103A1 (en)	2019-02-13	2020-08-20	The Brigham And Women's Hospital, Inc.	Anti-peripheral lymph node addressin antibodies and uses thereof
BR112021017604A2 (pt)	2019-03-06	2021-11-16	Glaxosmithkline Ip No 2 Ltd	Compostos úteis na terapia para hiv
CA3136443A1 (en)	2019-04-12	2020-10-15	Riboscience Llc	Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
EP4009982A4 (en)	2019-08-05	2023-08-09	Marinus Pharmaceuticals, Inc.	GANAXOLONE FOR USE IN TREATMENT OF STATUS EPILEPTICUS
JP2022543319A (ja)	2019-08-08	2022-10-11	グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッド	Ｈｉｖ治療に有用な化合物
US20220298160A1 (en)	2019-08-28	2022-09-22	Glaxosmithkline Intellectual Property (No.2) Limited	Compounds useful in hiv therapy
WO2021072325A1 (en)	2019-10-11	2021-04-15	Corbus Pharmaceuticals, Inc.	Compositions of ajulemic acid and uses thereof
JP7780431B2 (ja)	2019-12-06	2025-12-04	マリナスファーマシューティカルズ，インコーポレイテッド	結節性硬化症の治療での使用のためのガナキソロン
CA3168146A1 (en)	2020-01-20	2021-07-29	Genzyme Corporation	Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
US12485166B2 (en)	2020-02-06	2025-12-02	Longhorn Vaccines And Diagnostics, Llc	Vaccines for the treatment and prevention of zoonotic infections
WO2021167840A1 (en)	2020-02-18	2021-08-26	Vtv Therapeutics Llc	Sulfoxide and sulfone glucokinase activators and methods of use thereof
KR20220158031A (ko)	2020-03-26	2022-11-29	피엘엑스 옵코 인코포레이티드	pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
KR20230004618A (ko)	2020-04-17	2023-01-06	젠자임 코포레이션	전신성 과염증 반응을 수반하는 병태 치료에 사용하기 위한 에클리타세르팁
TW202206076A (zh)	2020-04-22	2022-02-16	美商普林斯匹亞生物製藥公司	使用ｂｔｋ抑制劑對急性呼吸窘迫症候群和其他涉及細胞激素風暴的病症之治療
CN121591674A (zh)	2020-06-08	2026-03-03	维特卫治疗有限责任公司	{2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途
EP3928772B1 (en)	2020-06-26	2024-06-19	Algiax Pharmaceuticals GmbH	Nanoparticulate composition
CA3182854A1 (en)	2020-07-09	2022-01-13	Rene Holm	Long-acting formulations
WO2022008643A1 (en)	2020-07-09	2022-01-13	Janssen Pharmaceutica Nv	Long-acting formulations
JP2023532981A (ja)	2020-07-09	2023-08-01	ヤンセンファーマシューティカエヌ．ベー．	長時間作用型配合物
GB2700078A (en)	2020-10-20	2025-09-17	Longhorn Vaccines & Diagnostics Llc	Immunogenic antigens
US11980636B2 (en)	2020-11-18	2024-05-14	Jazz Pharmaceuticals Ireland Limited	Treatment of hematological disorders
CN112451520B (zh) *	2020-12-31	2021-10-15	江苏宇锐医药科技有限公司	一种缬沙坦氨氯地平组合物及其制备方法
US20240182510A1 (en)	2021-02-23	2024-06-06	Viiv Healthcare Company	Compounds Useful in HIV Treatment
WO2023023473A1 (en)	2021-08-16	2023-02-23	Sierra Oncology, Inc.	Methods of using momelotinib to treat chronic kidney disease
US12569499B2 (en) *	2021-08-31	2026-03-10	Natsar Pharmaceuticals, Inc.	Intravenous formulations of RK-33
WO2023239727A1 (en)	2022-06-06	2023-12-14	The Usa, As Represented By The Secretary, Dept. Of Health And Human Services	Lats inhibitors and uses thereof
WO2023244672A1 (en)	2022-06-14	2023-12-21	Assembly Biosciences, Inc.	2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
EP4547249A1 (en)	2022-06-30	2025-05-07	Principia Biopharma Inc.	Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
EP4551556A1 (en)	2022-07-06	2025-05-14	Vividion Therapeutics, Inc.	Pharmaceutical compositions comprising wrn helicase inhibitors
MA71390A (fr)	2022-07-06	2025-04-30	Vividion Therapeutics, Inc.	Compositions pharmaceutiques comprenant des inhibiteurs de l'hélicase wrn
WO2024068699A1 (en)	2022-09-28	2024-04-04	Janssen Pharmaceutica Nv	Long-acting formulations
WO2024068693A1 (en)	2022-09-28	2024-04-04	Janssen Pharmaceutica Nv	Long-acting formulations
WO2024081168A1 (en)	2022-10-11	2024-04-18	Genzyme Corporation	Therapeutic tyrosine kinase inhibitors for multiple sclerosis
CN115844821B (zh) *	2023-01-03	2024-05-17	江苏知原药业股份有限公司	一种地奈德纳米晶混悬液、制备方法及其应用
WO2025128898A1 (en)	2023-12-13	2025-06-19	Assembly Biosciences, Inc.	Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections
WO2025144874A1 (en)	2023-12-24	2025-07-03	The Roskamp Institute	Potent nf-kb inhibitors for the treatment of inflammatory diseases
WO2026050513A1 (en)	2024-08-30	2026-03-05	Principia Biopharma Inc.	Tolebrutinib for multiple sclerosis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2671750A (en) *	1950-09-19	1954-03-09	Merck & Co Inc	Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
US3192118A (en) *	1964-04-23	1965-06-29	Fmc Corp	Cellulose crystallites radiopaque media
US4107288A (en) *	1974-09-18	1978-08-15	Pharmaceutical Society Of Victoria	Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DK143689C (da) *	1975-03-20	1982-03-15	J Kreuter	Fremgangsmaade til fremstilling af en adsorberet vaccine
DE3013839A1 (de) *	1979-04-13	1980-10-30	Freunt Ind Co Ltd	Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
SE8204244L (sv) *	1982-07-09	1984-01-10	Ulf Schroder	Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4826689A (en) *	1984-05-21	1989-05-02	University Of Rochester	Method for making uniformly sized particles from water-insoluble organic compounds
US4663364A (en) *	1984-09-05	1987-05-05	Kao Corporation	Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
GB8601100D0 (en) *	1986-01-17	1986-02-19	Cosmas Damian Ltd	Drug delivery system
NL194638C (nl) *	1986-12-19	2002-10-04	Novartis Ag	Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
DE3722837A1 (de) *	1987-07-10	1989-01-19	Ruetgerswerke Ag	Ophthalmisches depotpraeparat
JP2773895B2 (ja) *	1989-04-25	1998-07-09	東京田辺製薬株式会社	ダナゾール組成物
SE464743B (sv) *	1989-06-21	1991-06-10	Ytkemiska Inst	Foerfarande foer framstaellning av laekemedelspartiklar
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
FR2660556B1 (fr) *	1990-04-06	1994-09-16	Rhone Poulenc Sante	Microspheres, leur procede de preparation et leur utilisation.

1991
- 1991-01-25 US US07/647,105 patent/US5145684A/en not_active Expired - Lifetime
1992
- 1992-01-15 CA CA002059432A patent/CA2059432C/en not_active Expired - Lifetime
- 1992-01-20 PT PT92200153T patent/PT499299E/pt unknown
- 1992-01-20 EP EP92200153A patent/EP0499299B1/en not_active Revoked
- 1992-01-20 AT AT92200153T patent/ATE195416T1/de not_active IP Right Cessation
- 1992-01-20 SG SG1996006361A patent/SG55104A1/en unknown
- 1992-01-20 DK DK92200153T patent/DK0499299T3/da active
- 1992-01-20 DE DE69231345T patent/DE69231345T2/de not_active Revoked
- 1992-01-20 ES ES92200153T patent/ES2149164T3/es not_active Expired - Lifetime
- 1992-01-22 NZ NZ241362A patent/NZ241362A/xx not_active IP Right Cessation
- 1992-01-23 MX MX9200291A patent/MX9200291A/es unknown
- 1992-01-24 HU HU9200226A patent/HU221586B/hu unknown
- 1992-01-24 IE IE021792A patent/IE920217A1/en not_active IP Right Cessation
- 1992-01-24 TW TW081100510A patent/TW247275B/zh not_active IP Right Cessation
- 1992-01-24 FI FI920321A patent/FI108333B/fi active
- 1992-01-24 NO NO920334A patent/NO303668B1/no not_active IP Right Cessation
- 1992-01-24 IL IL10075492A patent/IL100754A/en not_active IP Right Cessation
- 1992-01-24 MY MYPI92000109A patent/MY108134A/en unknown
- 1992-01-24 JP JP01122692A patent/JP3602546B2/ja not_active Expired - Lifetime
- 1992-01-24 RU SU925010891A patent/RU2066553C1/ru active
- 1992-01-25 KR KR1019920001077A patent/KR100200061B1/ko not_active Expired - Lifetime
2000
- 2000-11-07 GR GR20000402448T patent/GR3034759T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUT62462A (en)	1993-05-28
FI920321L (fi)	1992-07-26
SG55104A1 (en)	1998-12-21
HU221586B (hu)	2002-11-28
ES2149164T3 (es)	2000-11-01
AU654836B2 (en)	1994-11-24
AU1014792A (en)	1992-07-30
GR3034759T3 (en)	2001-02-28
IL100754A (en)	1996-10-16
MX9200291A (es)	1992-10-01
ATE195416T1 (de)	2000-09-15
DK0499299T3 (da)	2001-01-02
KR920014468A (ko)	1992-08-25
KR100200061B1 (ko)	1999-06-15
NO920334L (no)	1992-07-27
EP0499299A2 (en)	1992-08-19
DE69231345T2 (de)	2001-04-26
JPH04295420A (ja)	1992-10-20
DE69231345D1 (de)	2000-09-21
NO303668B1 (no)	1998-08-17
CA2059432A1 (en)	1992-07-26
EP0499299B1 (en)	2000-08-16
HU9200226D0 (en)	1992-04-28
IL100754A0 (en)	1992-09-06
IE920217A1 (en)	1992-07-29
FI920321A0 (fi)	1992-01-24
RU2066553C1 (ru)	1996-09-20
EP0499299A3 (en)	1993-03-03
CA2059432C (en)	2003-03-18
FI108333B (fi)	2002-01-15
US5145684A (en)	1992-09-08
NO920334D0 (no)	1992-01-24
PT499299E (pt)	2001-01-31
MY108134A (en)	1996-08-15
NZ241362A (en)	1993-06-25
JP3602546B2 (ja)	2004-12-15

Legal Events

Date	Code	Title	Description
2012-03-01	MK4A	Expiration of patent term of an invention patent

Publication	Publication Date	Title
TW247275B (zh)	1995-05-11
HU9403543D0 (en)	1995-02-28	Surface modified nsaid nanoparticles
DK0577215T3 (da)	2000-08-28	Fremgangsmåde til fremstilling af overflademodificerede anticancer-nanopartikler
AU637423B2 (en)	1993-05-27	Method of treating or coating a substrate with an aqueous composition and the use of such compositions
EP0319557A4 (en)	1991-05-08	Reconstituted hdl particles and uses thereof
AU4245289A (en)	1990-04-05	Psyllium-containing products
CA2111758A1 (en)	1994-06-19	Personal Care Compositions
AU4189293A (en)	1994-01-13	A psyllium-hydrocolloid gum composition
WO1994013304A3 (en)	1994-09-01	Antacid composition and method of production